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ABSTRACT 
 
The aim of this thesis was to study the effects of milk and its processing on gastrointestinal symp-
toms and immune responses, with special reference to conditions not related to immunoglobulin E.  
Some people appear to experience cow’s milk-related symptoms even though neither lactose 
intolerance nor cow’s milk allergy (CMA) can be diagnosed. The cause of these symptoms is un-
clear, and apparently an unknown type of cow’s milk hypersensitivity exists. It has been suggested 
that the processing of cow’s milk may be involved in the induction of gastrointestinal symptoms. 
Homogenisation has been claimed as one possible cause. In this thesis, no difference in the toler-
ance to homogenised and unhomogenised milk was found, either in adults who had subjectively 
experienced better tolerance to unhomogenised than homogenised milk, or in lactose-intolerant 
adults, nor were any differences in the concentrations of milk protein-specific antibodies during 
open challenges with unhomogenised and homogenised milk found in milk-tolerant adults.  
This thesis includes studies of immunological background and of the mechanism of delayed-
type gastrointestinal CMA. The children with delayed CMA, diagnosed by an open cow’s milk 
challenge and an endoscopic examination, showed local intestinal activation of both T helper 1 
(Th1) and Th2 lymphocytes. The release of interferon  and the expression of interleukin 6 (IL-6) 
and chemokine receptor CC 4 (CCR-4) mRNA were up-regulated in the intestinal mucosa of these 
children, and in those with delayed CMA who consumed milk, increased local secretion of IL-4 
and IL-10 and decreased secretion of transforming growth factor  (TGF-) were found. 
The aim of the population-based study was to evaluate the occurrence of similar hypersensitiv-
ity against milk proteins in young adults with gastrointestinal complaints, as described in younger 
children earlier. However, no such cases with intestinal lymphonodular hyperplasia were found. Of 
the young adults, 10% reported major gastrointestinal complaints, 24% reported cow’s milk-
induced gastrointestinal symptoms and 13% did not drink any milk as such (n=827). However, in a 
blind challenge with a subgroup, cow’s milk protein-induced symptoms were rare and similar to 
those of a placebo soy drink. The elevation of soluble intercellular adhesion molecule 1 (sICAM-
1) in the plasma, and a tendency towards up-regulation of TGF- and IL-12p35 mRNA expression 
in the intestinal mucosa of the symptomatic subjects who volunteered for clinical examination, 
indicate a possible immunological nature of the identified gastrointestinal disorder. The food-
related gastrointestinal symptoms of young adults seemed to be caused by unspecific and unknown 
characteristics of altered mucosal immune response rather than being triggered by cow’s milk, as 
is often suspected by the patients themselves. This new entity of intestinal immune-mediated dis-
order may be a self-perpetuating disease with fluctuating symptoms. An autoimmune nature of the 
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state, at least in a subgroup of the affected subjects, cannot be ruled out, and this hypothesis is 
supported by the observation that the human leukocyte antigen DQ*02 allele, which predisposes to 
autoimmunity, was almost twice as common among the symptomatic individuals as among the 
rest. 
According to this series of studies, some young adults and some mature adults subjectively ex-
perience cow’s milk-related symptoms, but often the symptoms cannot be objectively diagnosed, 
and homogenisation of milk does not seem to be the cause of them. In children, delayed-type 
CMA seems to be a local intestinal immune-activation state showing activation of both Th1 and 
Th2 lymphocytes. The findings of immunological activity in young adults imply the existence of a 
food-related gastrointestinal syndrome, which is not, however, induced by cow’s milk. 
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TIIVISTELMÄ (Abstract in Finnish) 
 
Tämän väitöskirjan tarkoituksena oli tutkia lehmänmaidon ja sen käsittelyn vaikutusta ruoansula-
tuskanavan oireisiin ja puolustusvasteisiin. Erityisen kiinnostuksen kohteena olivat reaktiot, jotka 
eivät liity immunoglobuliini E:hen. 
Jotkut ihmiset kokevat saavansa lehmänmaidosta oireita, vaikka heillä ei voida osoittaa olevan 
laktoosi-intoleranssia eikä maitoallergiaa. Näiden oireiden syy on epäselvä, ja mitä ilmeisimmin 
tuntematon maitoyliherkkyyden muoto on olemassa. Maidon prosessoinnin on esitetty aiheuttavan 
vatsaoireita. Esimerkiksi maidon homogenointia on syytetty. Tässä väitöskirjassa homogenoidun 
ja homogenoimattoman maidon siedossa ei havaittu eroa aikuisilla, jotka kokivat sietävänsä ho-
mogenoimatonta paremmin kuin homogenoitua, eikä laktoosi-intoleranteilla aikuisilla. Maitoa 
sietävillä aikuisilla ei havaittu eroa maitoproteiinia kohtaan esiintyvien vasta-aineiden määrissä 
homogenoidun ja homogenoimattoman maidon nauttimisen aikana.  
Tässä väitöskirjassa tutkittiin viivästyneen maitoallergian immunologista taustaa ja mekanis-
mia. Lapsilla, joilla oli viivästynyt maitoallergia, havaittiin sekä auttaja T 1 (Th1) että Th2 lymfo-
syyttien paikallinen aktivoituminen suolen limakalvolla. Näillä lapsilla interferoni :n eritys, ja 
interleukiini (IL) 6:n ja kemokiinireseptori CC 4:n (CCR-4) mRNA:n ilmentyminen olivat lisään-
tyneet suolen limakalvolla. Lisäksi niillä maitoallergisilla lapsilla, jotka käyttivät maitoa, havaittiin 
IL-4:n ja IL-10:n paikallisen erityksen lisääntyneen ja transformoiva kasvutekijä :n (TGF-) eri-
tyksen vähentyneen. 
Väestötutkimuksen tarkoituksena oli arvioida samanlaisen maitoproteiiniyliherkkyyden esiin-
tymistä vatsaoireisilla nuorilla aikuisilla, mikä on aikaisemmin osoitettu nuoremmilla lapsilla. Tut-
kimuksessa ei kuitenkaan löytynyt yhtään vastaavaa tapausta, jossa olisi havaittu suolen imuku-
doslisää. Nuorista aikuisista 10 % kertoi kärsivänsä vakavista ruoansulatuskanavanoireista, 24 % 
raportoi saavansa oireita maidosta ja 13 % ei juonut maitoa (n=827). Osalle nuorista tehdyssä sok-
kokokeessa lehmänmaidon aiheuttamat oireet olivat harvinaisia ja lumesoijajuoman aiheuttamia 
oireita vastaavia. Intersellulaarisen adheesiomolekyyli 1:n (sICAM-1) lisääntyminen plasmassa ja 
suunta kohti TGF- ja IL-12p35 mRNA:n ilmentymisen lisääntymistä ohutsuolen limakalvolla 
tukevat löydetyn ruoansulatuskanavan oireyhtymän immunologista luonnetta. Ruokaan liittyvät 
ruoansulatuskanavan oireet näyttävät aiheutuvan nuorilla aikuisilla epämääräisestä ja tuntematto-
masta syystä eikä lehmänmaidosta, vaikka potilaat usein epäilevät lehmänmaidon yhteyttä oirei-
siin. Tämä uusi puolustusvasteen välittämä suoliston oireyhtymä voi olla itsestään syntyvä sairaus, 
jossa oireiden vaikeusaste vaihtelee. Taudin autoimmuuniluonnetta ei voida sulkea pois, ainakaan 
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osalla potilaista, ja teoriaa kannattaa havainto, että autoimmuunitauteihin liittyvä HL-antigeenin 
DQ*02 alleeli oli lähes kaksi kertaa yleisempi oireilevilla potilailla verrattuna muihin. 
Tämän väitöskirjatutkimuksen mukaan osa nuorista aikuisista ja aikuisista kokee saavansa 
maidosta oireita, mutta oireita ei usein voida diagnosoida objektiivisesti, eikä maidon homo-
genoinnilla näytä olevan yhteyttä oireisiin. Lapsilla viivästynyt maitoallergia näyttää olevan puo-
lustusvasteen tila, jossa sekä Th1 että Th2 lymfosyytit ovat aktivoituneet paikallisesti suolessa. 
Nuorilla aikuisilla havaittu puolustusvasteen aktivoituminen puoltaa ruokaan liittyvän ruoansula-
tuskanavan oireyhtymän esiintymistä, joka ei kuitenkaan näytä olevan lehmänmaidon aiheuttama. 
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INTRODUCTION 
 
The prevalence of allergic diseases is increasing in western countries. The functions of the gut and 
the mucosal immune system are crucial in the induction of oral tolerance or allergic sensitisation to 
luminal antigens. Cow’s milk allergy (CMA) is usually the first major food allergy, since cow’s 
milk proteins are the first source of foreign antigens massively ingested in infancy. In several large 
clinical trials, the cumulative prevalence of allergy to cow’s milk has been approximately 2-3% 
during the first years of life in the general population (Høst & Halken 1990, Schrander et al. 1993, 
Saarinen et al. 1999). The overall prognosis of CMA in infancy is good, with a remission rate of 
up to 85 or 90% (Høst 2002).  
In recent years recovery from CMA has become a subject of controversy. Compared to the 
mainly immunoglobulin (Ig) E-mediated CMA of infants and small children, a new form of de-
layed-type gastrointestinal cow’s milk hypersensitivity, also called cow’s milk sensitive enteropa-
thy, has been described in school-aged children and in adults, and it may be more common than 
previously thought (Bengtsson et al. 1996a, Pelto et al. 1998, Pelto et al. 1999, Ulanova et al. 
2000, Kokkonen et al. 2001a, Lin et al. 2002, Magnusson et al. 2003, Kokkonen et al. 2004). After 
childhood, reactions towards milk are rarely IgE-mediated, and virtually only case reports of IgE-
mediated CMA in adults exist.  
Self-diagnosed cow’s milk-related symptoms are commonly reported in questionnaires and in-
terviews (Pelto et al. 1999, Haapalahti et al. 2004, Kokkonen et al. 2004). Some individuals claim 
that they are intolerant to cow’s milk, even though neither lactose intolerance nor CMA can be 
diagnosed. Some declare that they tolerate raw untreated cow’s milk and unhomogenised, pasteur-
ised cow’s milk but show reactions of intolerance to homogenised and pasteurised commercial 
cow’s milk and dairy products. The parents of certain children who are allergic to cow’s milk re-
port the same phenomenon. However, in clinical studies, no difference in the tolerance of ho-
mogenised and unhomogenised cow’s milk has been observed (Hansen et al. 1987, Høst et al. 
1988, Pelto et al. 2000). 
The aim of this study was to examine the effects of cow’s milk and its processing on symptoms 
and intestinal immune activation in subjects with cow’s milk intolerance or delayed-type CMA, 
and to study the occurrence of milk-related reactions and subjective symptoms in relation to veri-
fied milk hypersensitivity in young adults. 
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REVIEW OF THE LITERATURE 
 
1  THE GUT IMMUNE SYSTEM 
1.1  Mucosal immunology 
 
The intestinal mucosa forms a major and critical barrier through which immunogenic particles and 
molecules such as food and microorganisms gain access to the immune system. The selective de-
fence mechanisms of the gut make possible the absorption of essential substances, and simultane-
ously reduce the absorption and injurious effects of the immunogenic particles (Table 1). The in-
testinal absorption of food antigens is closely dependent on developmental and environmental fac-
tors, including the maturity of the intestinal mucosa, the sites of absorption (Peyer’s patches), in-
testinal microbiota, and the presence of inflammation or infection (Heyman 2001). 
 
Table 1   Barriers to macromolecular absorption. Antigen entry is prevented by immunological and non-
specific mechanisms in the gastrointestinal tract as well as by the physiological structure of the 
epithelium itself (modified from Sanderson and Walker 1999).  
Mechanism Action 
Immunological barrier  
Humoral: secretory IgA and IgM and other Ig Neutralisation and removal of antigens 
Cell-mediated: lymphocytes of epithelium and  
lamina propria 
Specific local defence 
Non-specific barrier  
Gastric acid Dissolution of antigens 
Digestive enzymes Dissolution of antigens 
Mucus coat and secretions Inhibition of absorption 
Humoral factors of innate immunity: lactoferrin,  
lysozyme, peroxidases 
Dissolution of antigens 
Normal microbiota Dissolution of antigens, inhibition of absorption 
Tight junctions of the epithelium Inhibition of absorption 
Hepatic filter Removal of antigens 
Ig, immunoglobulin 
 
Classical effector cells of immune reactions, such as lymphocytes, dendritic cells, macro-
phages, eosinophils, mast cells and occasional neutrophils, are normally present or lie in close 
proximity to the epithelial layer. These cells and their intermediators constitute the immune sys-
tem, which can be divided into innate immunity and adaptive immunity (Fig. 1). 
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IMMUNE 
SYSTEM
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NK cells, acute
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Enzymes, 
transferrin etc.
Humoral
immunity
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TNF-α
TNF-β
Antigen-
presenting
Plasma 
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Immuno-
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Antigen-
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IL-10
TGF-β
IFN-γ
IL-2 
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cell-mediated
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IL-4 
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Figure 1  Diagrammatic representation of the human immune system. DC, dendritic cell; IFN-, inter-
feron ; IL, interleukin; NK cell, natural killer cell; Th, T helper lymphocyte; TNF, tumor ne-
crosis factor. 
 
Intestinal antigen handling determines the immune response to that antigen (Mayer 2000) (Fig. 
2). Antigens are absorbed from the gut mainly through the epithelial cells, but some of large mole-
cules may leak between the epithelial cells, and some antigens are absorbed intact through the M-
cells and carried by antigen-presenting cells into the Peyer’s patch follicles, an important factor in 
the development of tolerance (Heyman 2001). Across the epithelium, antigens are absorbed along 
two functional pathways. The main, degradative pathway reduces the immunogenicity of the anti-
gen. A minor pathway allows the transport of intact proteins. Increased intestinal permeability and 
altered antigen transference across the intestinal mucosa has been reported in states with hyper-
reactivity to environmental antigens, such as atopic eczema and CMA (Jalonen 1991, Majamaa & 
Isolauri 1996). 
Intact or partially digested antigens which pass through the epithelial barrier of the gut encoun-
ter the gut-associated lymphoid tissue (GALT) (Spahn & Kucharzik 2004). The GALT is a very 
well-developed immune network which protects the host from ingested pathogens and also pre-
vents host adverse immune reactions to ingested dietary protein. The interaction of orally adminis-
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tered food antigens with the GALT induces characteristic immunological responses such as the 
production of secretory IgA and the induction of oral tolerance.  
 
1.2 Direct
pathway
1.1 Degradative
pathway
Mast cell
Lumen
Intestinal epithelium
IFN-gamma
& TNF-alfa
Dietary
antigens
1. Transcellular pathway
MHC I MHC II
2. Paracellular pathway 3. Through M cells
PP
Peptidic
epitopes
Native antigens
APC APC
MHC II
M cell
APC
Y Y IgE
CD8+
APC
CD4+ CD4+
 
 
Figure 2 Diagrammatic representation of antigen absorption and outcome of antigen presentation, show-
ing that the outcome differs depending on the inflammatory environment (modified from Hey-
man 2001, Strobel 2001). APC, antigen-presenting cell; IFN-, interferon ; IgE, immu-
noglobulin E; MHC, major histocompatibility complex; PP, Peyer’s patch; TNF-, tumor ne-
crosis factor   
 
The main inductive sites of the GALT are Peyer’s patches, the organised lymphoid aggregates 
in the wall of the small and large intestine. The primary effector sites of mucosal immunity are the 
lamina propria, which contain T and B lymphocytes and other cells necessary for adaptive immune 
responses, and the epithelium, which contains a unique population of T cells called intraepithelial 
lymphocytes. T lymphocytes can be divided into those expressing  T-cell receptors (TCRs) for 
antigens and those expressing  TCRs. Lamina propria T cells mainly express  TCRs and CD4, 
while intraepithelial T cells contain a much higher percentage of + T cells and have predominant 
CD8 expression, suggesting reaction to antigens in a class I major hiscompatibility complex re-
stricted fashion (Lefrançois & Puddington 1999).  
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1.2  Local intestinal allergic reactions 
 
Oral tolerance is defined as a state of immunological unresponsiveness to an antigen induced by 
the ingestion of that antigen (Strobel 2001). Oral tolerance is the immunological mechanism by 
which the mucosal immune system maintains unresponsiveness to the numerous antigens which 
might otherwise induce damaging immune responses. It appears to be mediated by several mecha-
nisms, such as the antigen-specific generation of T cells which produce antigen non-specific regu-
latory cytokines. The development of oral tolerance is part of normal immunologic maturation, and 
IgE sensitisation to dietary antigens rather than tolerance may often occur in infancy, because of 
the immaturity of the gut or the intestinal lymphoid tissue or both. Intact antigens may penetrate 
the immature mucosa and induce an immunologic inflammatory reaction, which disappears when 
the infant grows up and the defence mechanisms develop. Increased intestinal permeability seems 
to be associated with the occurrence of mucosal inflammation and a lack of oral tolerance, i.e. al-
lergic reactions (Jalonen 1991, Majamaa & Isolauri 1996, Kalach et al. 2001), celiac disease (Kui-
tunen & Savilahti 1996) and autoimmune diseases (Kuitunen et al. 2002), and is also found in 
premature infants (Boehm et al. 1992). In healthy full-term infants, growth factors in colostrum 
milk activate the maturation of the intestinal mucosa so that gut closure and a normal permeability 
are rapidly observed after birth (Vukavic 1984, Catassi et al. 1995). During the first months of life 
the production of secretory IgA is insufficient in the gut of an infant, and instead, the secretory IgA 
of human milk neutralises antigens.  
 
Humoral immunity, IgE 
Atopic reaction type
Cell-mediated immunity
Autoimmune diseases
IL-4, IL-5, 
IL-6
Infection
Endotoxin
IL-12
Th2
IL-4, IL-5, 
IL-13
Th1
IFN-g,
IL-2
Naïve
Th
Helminths
Allergen
IFN-g
IL-4
Treg?
Treg?
 
 
Figure 3  Differentation of naïve CD4+ T cells in response to environmental factors, cytokines and the 
possible controlling effect of regulative T cells (modified from Ngoc et al. 2005). Th, T helper 
lymphocyte; Treg, T regulative lymphocyte 
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Interactions between T and B lymphocytes and certain regulatory cytokines influence the ini-
tiation and maintenance of allergic responses (Fig. 3). The immunological regulatory system of an 
infant favours allergic reaction type, because the T helper lymphocyte 1 (Th1) reactions are re-
strained during the embryonic stage (Dealtry et al. 2000). Upon antigen contact, CD4+ Th2 cells 
reinforce humoral immunity through the activation of B cells and the production of interleukin 4 
(IL-4), IL-5 and IL-10, which direct the immunoglobulin class switch to IgE and IgG1 and stimu-
late eosinophils (Kuhn et al. 1991, Torres et al. 2004). IL-13, which has the same homology as IL-
4, also stimulates IgE production and immediate-type hypersensitivity reactions (Hajoui et al. 
2004). In atopic infants the maturation of oral tolerance is prevented and new antigen contacts re-
inforce the Th2-type response. Healthy infants may also produce specific IgE antibodies against 
dietary antigens during the first months of life. However, soon antigen, microbe and virus stimula-
tions induce Th1-type cytokines, and Th1/Th2 balance is achieved through immune deviation. Th1 
cells mainly produce interferon  (IFN-) and IL-2 upon activation and reinforce cell-mediated 
immunity, phagocytosis and delayed-type hypersensitivity tissue damage. IFN- balances the ef-
fects of IL-4 and antagonises the production of IgE (So et al. 2000). 
The immune mechanisms involved in allergy are complex and cannot be explained by a simple 
shift from Th2 to Th1 immune responses. If reduced microbial exposure impaired the immune 
deviation from Th2 to Th1, one would not expect to see an increased prevalence of both autoim-
mune diseases (Th1-dominant immune responses) and allergic diseases (Th2-dominant immune 
responses). In fact, allergic sensitisation may be due to inadequate regulatory responses of the T 
cells rather than Th1/Th2 imbalance (Yazdanbakhsh et al. 2002, Karlsson et al. 2005), and the 
dominant immunological abnormality in the small bowel of food-allergic children may be a failure 
to establish normal numbers of the transforming growth factor  (TGF-) which produces regula-
tory cells (Chung et al. 2002, Pérez-Machado et al. 2003). The reduction of intestinal regulatory 
lymphocyte numbers may lead to a lack of bystander tolerance, and thus a tendency for multiple 
sensitisations (Groux & Powrie 1999, Strobel 2001). A recent study showed that induction of oral 
tolerance in children with CMA was associated with the appearance of circulating CD4+CD25+ 
regulatory T cells capable of suppressing the effector T cells generated by oral administration of 
dietary antigens (Karlsson et al. 2005).  
The possible role of the intestinal microbiota in the maturation of the immune system in infants 
and in the development of oral tolerance against foods has received considerable attention. Ac-
cording to animal and in vitro studies, the intestinal microbiota seems to stimulate the maturation 
of immune responses (Smits et al. 2004), and probiotic strains of lactobacilli are of particular in-
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terest in this respect (Vaarala 2003). Differences in intestinal Bifidobacterium flora composition 
have been reported between infants in Sweden, with a high incidence of atopic disease, and in Es-
tonia, with low incidence, and between allergic and healthy children (Sepp et al. 1997, Björkstén et 
al. 1999, Björkstén et al. 2001, Ouwehand et al. 2001, Watanabe et al. 2003). The reduction of 
bifidobacteria has been shown to precede the development of atopic disease, suggesting an essen-
tial role of the balance of indigenous intestinal bacteria for the maturation of human immunity to a 
non-atopic mode (Kalliomäki et al. 2001a). Indeed, a probiotic Lactobacillus strain GG has been 
shown to reduce symptoms in infants with atopic dermatitis (Majamaa & Isolauri 1997, Isolauri et 
al. 2000, Viljanen et al. 2005a), and to prevent early atopic disease in children at high risk (Kal-
liomäki et al. 2001b, Rautava et al. 2002). The anti-allergenic effects of probiotics may be medi-
ated by the stimulation of Th1 cytokines (Maassen et al. 2000, Pohjavuori et al. 2004, Adel-Patient 
et al. 2005), or of secretory gut IgA (Ibnou-Zekri et al. 2003, Viljanen et al. 2005b), and also by 
the induction of sufficient responses, even low-grade inflammation, in the gut epithelium and 
macrophages in order to allow the effective generation of regulatory lymphocyte populations (Iso-
lauri et al. 2000, Paganelli et al. 2002, Viljanen et al. 2005c). 
These findings of microbiota, probiotics and atopic diseases support a so-called hygiene hy-
pothesis: the rapid increase in atopy may be related to less exposure to environmental microbes 
and infections in infancy, because the immune response to microbial antigens drives the expres-
sion of Th1 cytokines and counterbalances Th2 cytokine production, continuation of which might 
lead to enhanced IgE production and atopic diseases (von Mutius 1998, Aalberse & Platts-Mills 
2004, Rautava et al. 2004, Romagnani 2004, Williams et al. 2004). However, studies opposed to 
the hygiene hypothesis also exist: in developing countries, microbes and infections do not seem to 
protect from atopy (Chai et al. 2004, Kramer et al. 2004).  
 
1.3  Immune mechanisms of gastrointestinal symptoms 
 
Many food-provoked symptoms such as nausea, vomiting, abdominal cramps, distension and diar-
rhoea are presumed to originate from the gastrointestinal tract. It is obviously difficult to find a 
specific immunological response and to diagnose a specific disease which might cause such com-
mon and generalised symptoms. The intensity of the symptoms is difficult to quantify objectively. 
The quantity of intestinal gas (Chami et al. 1991, Koide et al. 2000) and the dilatation of the bowel 
(Whitehead et al. 1990) have been measured, often with poor correlation to the symptoms, and 
therefore a written symptom record is still the most common way of assessing the symptoms. Fur-
thermore, some patients may have abnormal pain response to gut distension, disordered intestinal 
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motility, an altered contractile activity of the gut, and an altered compliance of the gut related to 
wall tension or muscle tone, or they may perceive intestinal stimuli diffusedly (Whitehead et al. 
1990, Accarino et al. 1995). 
The monocytes/macrophages and other antigen-presenting cells are important in processing an-
tigens and presenting them to the lymphocytes in such a way that an appropriate immune response 
is triggered. Intestinal diseases are often associated with an increased permeability to macromo-
lecular food antigens which, after penetration to the intestinal lumen, can stimulate the underlying 
immune system. The release of cytokines and inflammatory mediators further enhances leakage 
through the epithelial barrier, leading to a vicious circle of inflammation (Chung et al. 2002). The 
well-known pro-inflammatory cytokine IFN- has been shown to disrupt tight junctions and to 
increase the paracellular permeability of the intestinal epithelium (Adams et al. 1993, Ferrier et al. 
2003).  
Celiac disease occurs in genetically susceptible individuals expressing the human leukocyte 
antigen (HLA) alleles HLA-DQ2 (DQA1*05-DQB1*02) or HLA-DQ8 (DQA1*0301-
DQB1*0302) haplotype (Green & Jabri 2003, Koning 2003). In celiac disease, it is mainly Th1-
type inflammatory IFN- but also Th2-type cytokines, e.g. IL-4, and macrophage-derived cyto-
kines, e.g. tumor necrosis factor  (TNF-), that have been shown to be up-regulated, and there is 
a massive increase of intraepithelial CD3+, αβ+ and γδ+ T cells (Kontakou et al. 1995, Forsberg et 
al. 2002, Olaussen et al. 2002, Westerholm-Ormio et al. 2002, Veres et al. 2003). The activation of 
the immune cascades is much weaker and less well-known in delayed-type gastrointestinal food 
allergy; however, an accumulation of lymphoid cells in the form of nodules and a mild increase of 
γδ+ T cells has been reported (Spencer et al. 1991, Kokkonen et al. 2000, Kokkonen et al. 2001b). 
Lacking villous atrophy and/or the accumulation of mononuclear cells in the lamina propria, the 
symptoms of delayed-type food allergy have been thought to originate from a cytokine imbalance, 
possibly an up-regulation of both Th2- and Th1-type cytokines (Wakefield et al. 2000, Veres et al. 
2003). The duodenal biopsies of children with gastrointestinal food allergy have shown up-
regulation of IFN-γ and, to a lesser extent, IL-4 secreting cells (Hauer et al. 1997, Veres et al. 
2003). Even though food-hypersensitive adults rarely have systemic food-specific IgE, they may 
have local allergic reaction in the intestinal mucosa, seen as high numbers of IgE-bearing cells, 
activated eosinophils and T cells (Lin et al. 2002). 
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2  CLASSIFICATION OF ADVERSE REACTIONS TO FOOD 
 
The mechanisms of adverse reactions to food are multiple (Fig. 4). Food aversion is a psychologi-
cal problem connected to the ingestion of particular foods, and would not occur if the food was 
presented in disguised form. Food intolerance is an unpleasant reproducible reaction to a specific 
food, which lacks either a psychological or a known immunological basis, and is based on other 
defined mechanisms or factors, such as pharmacological ones (caffeine), enzyme deficiency (lac-
tase, sucrase), or non-specific histamine release (strawberries, see chapter 2.2). Food hypersensi-
tivity/allergy is defined as an adverse reaction to food mediated by dietary antigens, where an 
involvement of the immune system can be demonstrated (see chapter 2.1).  
 
Adverse
reactions
to food
Food 
aversion
Food 
hyper-
sensitivity/
allergy
Celiac disease
and other food 
sensitive
enteropathies
Non-IgE-
mediated
allergy
Food
intolerance
Predictable reac-
tions: pharma-
cological effects, 
toxins, contami-
nants, microbes
Errors of meta-
bolism e.g. 
hypolactasia
Idiosyncratic re-
actions: non-IgE
mast cell de-
granulation, IBS
IgE-mediated
allergy
 
 
Figure 4 Classification of adverse reactions to food (modified from Fickling & Robertson 2002a, Fick-
ling & Robertson 2002b). IBS, irritable bowel syndrome 
 
Despite such apparent clear-cut definitions, diagnosis at clinical level is far more difficult to 
establish. For example, an obvious gap exists between self-reported food-related allergic symp-
toms and those that can be objectively confirmed by a double-blind placebo-controlled food chal-
lenge (Jansen et al. 1994, Young et al. 1994, Roehr et al. 2004, Zuberbier et al. 2004). Nor is it 
always possible to demonstrate the involvement of the immune system in non-IgE-mediated al-
lergy. 
 
REVIEW OF THE LITERATURE 
  
 21 
2.1  Food allergy 
 
Food allergy is triggered by an aberrant immune response elicited by the oral administration of 
dietary antigens. Systemic exposure to an antigenic stimulus leads to the development of specific 
antibodies and of cell-mediated immunity. In most cases, continuous exposure leads to tolerance, 
the specific state of unresponsiveness. Allergic reactions are traditionally classified under four 
types of hypersensitivity reaction which may lead to tissue damage, as described by Coombs and 
Gell (see Britton 2002, Hay & Westwood 2002, Male 2002, Platts-Mills 2002). It is not clear 
whether all four types of reaction are involved in the pathogenesis of food allergy, either in the gut 
itself or in remote organs. More than one mechanism may be involved in any allergic reaction, but 
the most plausible mechanisms are IgE-mediated reactions (Type I), and the non-IgE-mediated 
activation of T lymphocytes (Type IV): allergies may be exclusively IgE-mediated, partially IgE-
mediated or exclusively cell-mediated (Sampson 2001). 
Type I, immediate anaphylactic hypersensitivity is characterised by the production of IgE 
antibodies against foreign proteins (Platts-Mills 2002). IgE antibodies bind to high-affinity FcRI 
receptors on mast cells and basophils. When an allergen binds between two IgE antibodies, it in-
duces degranulation of a mast cell/basophil, which leads to the rapid release of histamine and the 
more gradual release of other mediators such as leukotrienes and cytokines. The combined effect 
of these agents is to constrict smooth muscle, dilate capillaries and induce cell infiltration. This 
mechanism underlies the common problem of atopic allergy. 
Type II, antibody-dependent cytotoxic hypersensitivity is an important part of the body’s 
normal humoral immune response (Male 2002). IgG or IgM antibodies identify cell-surface anti-
gens on foreign antigens or an individual’s own cells, such as transformed red blood cells, then 
activate the complement system and damage the cell. Killer cells, platelets, neutrophils, eosino-
phils and mononuclear phagocyte cells have receptors for IgG and the activated C3b components 
of the complement system, and can therefore cause Type II lytic damage to the target cells. 
Type III, immune-complex-mediated hypersensitivity is complement and effector-cell me-
diated tissue damage (Hay & Westwood 2002). Food antigens are often absorbed from the gut in 
small amounts and may form immune complexes with specific antibodies in the circulation, espe-
cially in atopic subjects (Paganelli et al. 1981). Generally, these complexes are effectively re-
moved by the mononuclear phagocyte system, but occasionally they persist, establish themselves 
in tissues and organs, and cause acute inflammation and tissue damage by activating the comple-
ment system. 
REVIEW OF THE LITERATURE 
  
 22 
Type IV, delayed cell-mediated hypersensitivity reactions take more than 12 hours to de-
velop (Britton 2002). T cells identify antigens, and the antigen-sensitised T cells produce cytokines 
and other soluble factors which mediate the hypersensitivity reaction, or else they develop cytotox-
icity. Th cell-activated macrophages destroy intracellular bacteria by releasing inflammatory me-
diators. Activated cytotoxic T cells and natural killer cells destroy virus-infected cells and trans-
formed human cells, i.e. cancer cells and tissue transplants. Tissue damage occurs as a result of 
persistent antigenic stimulation, either because of continuing infection or because of autoimmuni-
sation. Type IV hypersensitivity has been classified under three varieties: contact hypersensitivity 
and tuberculin-type hypersensitivity, which both occur within 3 days of a challenge; and granulo-
matous hypersensitivity reactions, which develop over a period of 21-28 days and are clinically the 
most serious of the Type IV responses. More than one type of delayed hypersensitivity may follow 
a single antigenic challenge, and reactions may overlap. 
 
2.2  Food intolerance 
 
Adverse reactions to food which do not involve the immune system are described as food intoler-
ances. Fickling and Robertson (2002b) have classified non-immunological adverse reactions into 
three main groups: 1) predictable reaction, 2) errors of metabolism, and 3) idiosyncratic reactions. 
Predictable adverse reactions to food are expected to occur in any individual exposed to that 
food, although individual variations in susceptibility may exist. Examples include the toxic effect 
of non-nutrients contained in foods (e.g. mushroom toxins, bean lectins, lead, cadmium); microbial 
contamination causing gastroenteritis; and the pharmacological effect of foods containing caffeine, 
salt, alcohol, natural laxatives, or biogenic amines (e.g. histamine, tyramine) (Denaro et al. 1991, 
Morrow et al. 1991, Kanny et al. 1993, Kanny et al. 1996). 
The most common error of metabolism is hypolactasia, in which the genetically determined 
reduction of lactase activity occurs after weaning (see chapter 3.4). Primary enzyme deficiencies at 
the time of birth are very rare, and comprise neonate hypolactasia and deficiencies of sucrase-
isomaltase, trehalase, or enteropeptidase as well as other rare deficiencies (Arola et al. 1999, Bel-
mont et al. 2002, Holzinger et al. 2002, Ritz et al. 2003). 
In idiosyncratic reactions, the mechanism of intolerance may be unclear but does not involve 
the immune system. Certain food polypeptides may bind to mast cell IgE receptors and induce the 
non-immunological release of histamine and other chemical mediators from mast cells. Strawber-
ries are the most common non-specific histamine releasers, but egg white, crustaceans, fish, toma-
toes and the proteases of pineapple and papaya have also been reported (Kanny & Moneret-
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Vautrin 2002). These ‘pseudoallergens’ may exacerbate atopic dermatitis or chronic urticaria 
(Worm et al. 2000, Buhner et al. 2004). Subjects with irritable bowel syndrome often relate the 
exacerbation of their symptoms to certain foods. The mechanisms and evidence of these reactions 
are unclear, and dietary manipulation frequently yields rather disappointing results (Dapoigny et 
al. 2003, Soares et al. 2004, Whorwell & Lea 2004). However, some studies suggest that food in-
tolerance is the cause of irritable bowel syndrome in approximately 50% of cases (Nanda et al. 
1989). Indigestible carbohydrates, such as sweeteners (Born et al. 1994, Storey et al. 2002), fructo-
oligosaccharides (Briet et al. 1995, Teuri et al. 1999) and galacto-oligosaccharides (Teuri et al. 
1998), induce gastrointestinal symptoms in certain subjects, possibly depending on the capability 
of the subject’s intestinal microbiota to produce gases, and the sensitivity of the subject to the feel-
ing of gastrointestinal swelling. 
 
3  ADVERSE REACTIONS TO COW’S MILK 
3.1  Different types of cow’s milk allergy 
 
CMA before school age 
CMA is usually the first major food allergy, since cow’s milk proteins are the first source of for-
eign antigens massively ingested in infancy. In several large clinical trials, the cumulative preva-
lence of allergy to cow’s milk has been approximately 2-3% during the first years of life in the 
general population (Jakobsson & Lindberg 1979, Hide & Guyer 1983, Bock 1987, Høst & Halken 
1990, Schrander et al. 1993, Saarinen et al. 1999). In atopic infants, however, the prevalence is up 
to 50% (Sampson & McCaskill 1985, Isolauri & Turjanmaa 1996, Niggemann et al. 1999). CMA 
has been reported even in exclusively breast-fed infants (Høst et al. 1988, Isolauri et al. 1999, Jär-
vinen et al. 1999, Österlund et al. 2004a). The majority of paediatric patients have symptoms from 
two or more organ systems: approximately 50-60% have cutaneous, 50-60% gastrointestinal and 
20-30% respiratory symptoms (Høst 2002). In exclusively breast-fed infants with CMA, severe 
atopic eczema is a predominant symptom. In infants under the age of one year, CMA is reportedly 
IgE-mediated in 57-64% of the cases (Vanto et al. 1999, Saarinen & Savilahti 2000). The overall 
prognosis of CMA in infancy is good, with a remission rate of 85 or 90% by 3 years of age (Høst 
& Halken 1990, Høst 2002), non-IgE-mediated reactions being the quickest to recover (Vanto et 
al. 2004).  
The basic treatment of CMA is complete avoidance of cow’s milk protein. The main allergens 
in cow’s milk protein are casein and whey proteins, -lactoglobulin and -lactalbumin (Jensen 
1995). The protein fraction of cow’s milk consists of at least 20-30 different proteins, all possible 
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allergens, and therefore hydrolysation of some main allergens does not help the majority of aller-
gic patients. Even though proof from repeated trials of double-blind placebo-controlled cow’s milk 
elimination diets is lacking, an elimination diet is believed to alleviate symptoms, preserve intesti-
nal integrity, prevent aberrant antigen absorption and reverse the disturbance of humoral and cell-
mediated immune response (Isolauri et al. 1992, Majamaa et al. 1996). However, the positive ef-
fect of an elimination diet may partially be explained by the fact that many children grow out of 
their allergies, and a cow’s milk elimination diet has been shown to be equally efficacious in the 
treatment of atopic dermatitis, both in children tolerant to cow’s milk and in children with CMA 
(Viljanen et al. 2005ac). According to the latest view, a continuous allergen load might maintain 
tolerance: in one case study, long term milk protein elimination led to fatal milk protein hypersen-
sitivity (Barbi et al. 2004); and a successful oral desensitisation to milk protein has been reported 
in children with IgE-mediated CMA (Meglio et al. 2004). The concept of the maintaining of oral 
tolerance vs. an elimination diet needs further research. Unnecessary food avoidance should be 
discouraged.  
 
CMA in school-aged children and adults 
In most textbooks CMA is considered to be rare in adults. Only a restricted number of studies on 
the immunological mechanisms of adult CMA exist, supported by either double-blind, placebo-
controlled milk challenges or the open challenge procedure (Nørgaard & Bindslev-Jensen 1992, 
Nørgaard et al. 1995, Bengtsson et al. 1996b, Bengtsson et al. 1996a, Bengtsson et al. 1997, Wer-
fel et al. 1997, Little et al. 1998, Ulanova et al. 2000, Lin et al. 2002, Magnusson et al. 2003). In 
recent years recovery from CMA has become a subject of controversy. Compared to the mainly 
IgE-mediated CMA of infants and small children, a new form of delayed-type gastrointestinal 
cow’s milk hypersensitivity, also known as cow’s milk sensitive enteropathy, has been described 
in school-aged children and adults, and it may be more common than previously thought 
(Bengtsson et al. 1996b, Bengtsson et al. 1996a, Bengtsson et al. 1997, Pelto et al. 1998, Pelto et 
al. 1999, Ulanova et al. 2000, Kokkonen et al. 2001a, Lin et al. 2002, Magnusson et al. 2003, 
Kokkonen et al. 2004). After childhood, reactions to milk are rarely IgE-mediated, and virtually 
only case reports of IgE-mediated CMA in adults exist. In one study, only 10% of the children 
with CMA in childhood had IgE-mediated reactions to milk protein at school age; however, half 
the children still reported gastrointestinal symptoms related to the ingestion of cow’s milk protein 
(Kokkonen et al. 2001a).  
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Figure 5 Top: In a 10-year-old boy who reacted in an elimination-challenge test to cow’s milk, an endo-
scopic view on the mucosa of the duodenal bulb shows numerous lymphoid nodules (left). A 
histology of the biopsy reveals a lymphoid nodule with a germinal centre but otherwise normal 
mucosal architecture with tall and slender villi (right). Below: Normal endoscopic view, nice 
villous architecture and slender, tall villi without lymphoid aggregations in a healthy individual. 
Photographs provided by Dr. Jorma Kokkonen (Oulu, Finland). 
 
The up-regulation of the local immune T cell responses in situ on the mucosa may cause milk-
related gastrointestinal reactions in delayed-type gastrointestinal CMA. In school-aged children, 
delayed CMA seems to be characterised by an endoscopic finding of patchy, sometimes diffuse, 
lymphonodular hyperplasia (LNH) involving the upper duodenum (Fig. 5), the terminal ileum 
and/or the colon, and by slightly elevated densities of intraepithelial γδ+ T cells (Kokkonen 1999, 
Kokkonen et al. 2000, Kokkonen et al. 2001c, Kokkonen et al. 2001b, Turunen et al. 2004). Typi-
cal features in a microscopic examination of the biopsy samples are increased frequency of lym-
phoid follicles with germinal centres and sometimes mildly increased density of eosinophilic leu-
kocytes, but neither villous atrophy nor the increase of mononuclear cell infiltration in lamina pro-
pria have been reported. These features are markedly different from those in subjects with celiac 
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disease or in small children with food allergy. Indeed, in one study children who reacted in a blind 
challenge exhibited LNH of the duodenal bulb but failed to show signs of markers for atopic food 
allergy as measured by positive skin-prick tests or food-specific IgE-class antibodies (Kokkonen et 
al. 2001b). In addition to the fact that non-invasive diagnosis is difficult, endoscopic assessment is 
hampered since the mucosal lesions associated with the immune responses may vary in severity 
and extent, and they may be patchy, involving various segments of the gastrointestinal tract.  
 
3.2  Diagnosis of cow’s milk allergy 
 
As no single laboratory test is diagnostic for either immediate or delayed-type CMA, the diagnosis 
still has to be based on strict, well-defined milk elimination and challenge procedures, and immu-
nologic measurements may aid the diagnosis (Table 2). The diagnosis of gastrointestinal cow’s 
milk hypersensitivity is by no means simple. The main symptoms are common to many conditions 
and it is difficult to distinguish between unspecific milk intolerance and milk allergy. Clinical his-
tory is crucial in the diagnosis, especially in infants who may have ingested only a few solid foods. 
 
Table 2 Diagnosis of immunoglobulin E (IgE)-mediated and delayed-type cow’s milk allergy, and ex-
perimental methods related to mechanism studies (modified from Terho et al. 1999). 
Diagnostic and experimental methods 
Clinical history 
Elimination diet 
Challenge, open/blind 
Skin prick test 
Measurement of milk protein-specific IgE from serum 
Atopy patch test 
Experimental methods 
Measurement of local/systemic cytokines 
Measurement of gut inflammation and permeability 
Local challenge during endoscopy 
Histamine release test 
 
In young infants, open controlled challenges have been shown to be reliable when performed 
under professional observation in a hospital (Høst & Halken 1990, Niggemann et al. 1994, Isolauri 
& Turjanmaa 1996). In children over 1-2 years of age and in adults, the double-blind placebo-
controlled food challenge is considered the gold standard for exclusion of psychological or causal 
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reactions (Høst & Halken 1990, Niggemann et al. 1994), but is often too laborious in clinical work 
(Kaila et al. 2000). In patients with delayed reactions, a placebo-controlled food challenge would 
be the best method of diagnosis (Bindslev-Jensen et al. 2004), but this is often not practical in 
clinical work. In adults in particular it may be difficult to distinguish gastrointestinal allergies from 
other gastrointestinal symptoms such as those of lactose intolerance or irritable bowel syndrome.  
In early infancy and especially in breast-fed infants who develop immediate reactions to cow’s 
milk, the presence of a specific elevation of IgE antibodies to cow’s milk or a skin prick test for 
cow’s milk may have diagnostic value. According to reports, the specificity of the skin prick test 
varies greatly, from 50 to 99%, and sensitivity, from 14 to 78%, when the cut-off size of the wheal 
diameter is set at 3 mm (Majamaa et al. 1999a, Vanto et al. 1999, Roehr et al. 2001, Saarinen et al. 
2001, Strömberg 2002, Rancé 2004). In these particular studies, the atopy patch test was found to 
have better specificity (71 to 100%), especially in patients with skin symptoms, but its sensitivity 
for identifying all the disease cases was comparatively low (from 26 to 89%). When quantitatively 
assessed by the CAP System FEIA, cow’s milk specific IgE antibody titres of over 32 kU/l have 
been reported to predict IgE-mediated CMA with as high as 95% certainty in atopic patients 
(Sampson & Ho 1997). However, this finding was not supported by a recent study in which much 
higher cow’s milk-specific IgE titres (88.8 kU/l) were needed for predicting CMA with 90% prob-
ability, and the authors concluded that no meaningful predictive decision point could be calculated 
for predicting CMA (Celik-Bilgili et al. 2005). Skin tests are rarely useful in adults (Nørgaard & 
Bindslev-Jensen 1992). Increased IgA and IgG milk antibodies are not diagnostic, but merely a 
sign that milk has been ingested. Basophil histamine release is more frequently measured in other 
food allergies (Hansen et al. 2003, Østerballe et al. 2003) than in CMA (Prahl et al. 1988), and has 
not usually been found to be more predictive than skin prick testing or milk-specific IgE testing.  
 
Experimental diagnostic methods in CMA 
Besides the diagnostic methods summarised above, a number of experimental methods have at-
tracted scientific interest and may be helpful for studies of the mechanisms of CMA. Exposure to 
cow’s milk enhances mucosal permeability and elicits inflammation in the gut in infants with 
CMA (Majamaa & Isolauri 1996), possibly through the synergistic action of TNF- and IFN- 
(Heyman et al. 1994, Benlounes et al. 1996). For example, a lactulose and mannitol permeability 
test can be used in clinical work (Jalonen 1991, Kalach et al. 2001). Permeability can also be 
measured from intestinal biopsy samples in vitro in the so-called Ussing chamber, which may also 
include an antigen challenge (Heyman et al. 1994, Majamaa & Isolauri 1996, Terpend et al. 1999). 
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 Markers of inflammation in the faeces, such as eosinophil protein X, eosinophil cationic pro-
tein, IgA, TNF- and -antitrypsin, have been reported as non-invasive indicators of intestinal 
inflammation in atopic infants with CMA (Majamaa et al. 1996, Majamaa et al. 1999b, Majamaa 
et al. 2001, Saarinen et al. 2002). Increased eosinophil activation, such as increased eosinophil 
protein X in faecal samples (Magnusson et al. 2003) and activated eosinophils in small intestinal 
biopsy specimens (Lin et al. 2002, Schwab et al. 2003), has also been reported in food allergic 
adults. Eosinophil activation may be used for detecting ongoing clinical or subclinical chronic in-
testinal inflammation. 
Cell-mediated reactions may be studied with the lymphocyte profileration test, which detects 
the proliferation activity of the patient’s lymphocytes when they are stimulated with milk antigens 
in vitro (Beyer et al. 2002). Cytokines released by lymphocytes in vitro to cell-culture media can 
be measured with an enzyme-linked immunosorbent assay (ELISA) (Heyman et al. 1994, 
Benlounes et al. 1996, Beyer et al. 2002). An enzyme-linked immunosorbent spot (ELISPOT) as-
say can be used to study the frequency of cells secreting certain cytokines (Suomalainen & Isolauri 
1994, Hauer et al. 1997, Järvinen et al. 1999). 
Chronic gastrointestinal allergy may cause marked mucosal injury, histological changes and 
the up-regulation of intraepithelial T cells in the small intestine and the colon (Kokkonen 1999, 
Kokkonen et al. 1999, Kokkonen et al. 2000, Kokkonen et al. 2001c, Kokkonen et al. 2001b, 
Veres et al. 2003). Mucosal changes during a local antigen challenge can be measured by endo-
scopy; challenges both of stomach and of colon (‘COLAP’, colonoscopic allergen provocation) 
have been reported (Bischoff et al. 1997a, Bischoff et al. 1997b). However, the procedure is labo-
rious and the results seem to be no more reliable than those achieved with a placebo-controlled 
food challenge. The measurement of serum complement changes during a placebo-controlled food 
challenge (Martin et al. 1984, Isolauri et al. 1997, Pelto et al. 2000), cell-surface markers of anti-
gen specific T cells (Schade et al. 2002), and T-cell signal transduction (Österlund et al. 2003) 
have all attracted scientific interest. 
 
3.3  Lactose intolerance 
 
In lactase deficiency the activity or concentration of the lactose cleaving enzyme -galactosidase, 
also called lactase, in the brush border of the small intestinal mucosa is insufficient. This hypolac-
tasia causes insufficient digestion of lactose, the major carbohydrate of milk, a phenomenon called 
lactose malabsorption or lactose maldigestion. As reviewed by Sahi (1994), lactose maldigestion 
affects approximately 60% of the world’s adult population, the prevalence varying in Europe from 
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2% in Scandinavia to 70% in Italy, 70-90% in South America, Africa and Asia, and reaching 
100% in some Asian countries. 
The forms of lactose maldigestion are 1) lactase non-persistence, 2) secondary lactose maldi-
gestion, and 3) rare congenital lactase deficiency. In lactase non-persistence, also called adult-
type lactose maldigestion, lactase activity is high at birth, decreases in a genetically programmed 
way in childhood and adolescence, and remains low in adulthood, which is the normal physiologi-
cal situation for humans and other mammals. In populations where lactase non-persistence is pre-
dominant, the loss of lactase begins soon after weaning, and vice versa – in populations with low 
prevalence of lactose maldigestion, it develops later in adolescence or even in early adulthood 
(Sahi et al. 1983, Sahi 1994). Lactase is found at the tip of the intestinal villi, and is therefore vul-
nerable to intestinal diseases, inflammation and chemotherapy, leading to a secondary form of 
lactose maldigestion. Typically, lactase activity returns after recovery from the original disease 
(e.g. celiac disease, Crohn’s disease, enteritis) and after the discontinuation of chemotherapy 
(Bode & Gudmand-Hoyer 1988, Murphy et al. 2002, Österlund et al. 2004b). A small intestinal 
resection may cause irreversible secondary lactose maldigestion. Congenital lactase deficiency is 
an extremely rare inheritable genetic defect, which is apparent immediately after birth (Savilahti et 
al. 1983). 
 Hypolactasia accompanied by clinical symptoms such as bloating, flatulence, nausea, diar-
rhoea, and abdominal pain is called lactose intolerance. The symptoms occur when undigested 
lactose passes to the large intestine, where it serves as a fermentable substrate for the microbiota 
and osmotically increases the flow of water into the lumen. The intensity of the symptoms depends 
on the amount of lactose ingested, on individual sensitivity, the rate of gastric emptying, gastroin-
testinal transit time, and the pattern of microbiota in the large intestine. Ingestion of 50 g lactose, 
the amount commonly used in clinical tolerance tests, causes symptoms in 80-100% of lactose 
maldigesters, whereas the ingestion of a glass of milk (200-250 ml) causes symptoms to only 30-
50% (Vesa et al. 2000). For some unknown reason, a small percentage of maldigesters remain 
symptom-free even after the ingestion of large amounts of lactose. Symptoms of lactose intoler-
ance can be reduced by food and meal pattern choices and by the consumption of low-lactose and 
lactose-free dairy products. Total avoidance of dairy products often results in poor calcium intake 
and an increased risk of fractures; so lactose intolerance is associated with reduced bone mineral 
density and may predispose to bone fractures (Jackson & Savaiano 2001, Kudlacek et al. 2002, 
Obermayer-Pietsch et al. 2004). Self-described "lactose-intolerant" individuals may restrict their 
dairy and calcium intake without real clinical need, and are at risk of osteoporosis and bone frac-
tures (Savaiano 2003). 
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Lactose digestion can be measured by direct or indirect methods (Arola 1994). The direct 
methods – the measurement of mucosal disaccharidases, and an intestinal perfusion technique for 
the exact measurement of lactose digestion – are laborious. The most widely-used indirect tests are 
the traditional lactose tolerance test (measurement of serum glucose), the lactose tolerance test 
with ethanol (measurement of serum galactose), the hydrogen breath test and the urinary galactose 
test. Genotyping for the C/C
-13910 variant of lactase persistence/nonpersistence is a new way of 
determining susceptibility to adult-type hypolactasia; however, it cannot be used as a diagnostic 
tool to determine lactose intolerance, as the age of reduction of lactase varies (Enattah et al. 2002, 
Kuokkanen et al. 2003, Rasinperä et al. 2004). 
 
3.4  Processing of milk and its potential gastrointestinal effects  
 
Self-diagnosed cow’s milk-related symptoms are commonly reported in questionnaires and inter-
views (Pelto et al. 1999, Haapalahti et al. 2004, Kokkonen et al. 2004). Some individuals claim to 
be intolerant to cow’s milk, even though neither lactose intolerance nor CMA can be diagnosed. In 
Nordic countries, a number of consumers claim that they tolerate raw untreated cow’s milk and 
unhomogenised pasteurised cow’s milk but show reactions of intolerance to homogenised and pas-
teurised commercial cow’s milk and other dairy products. The parents of certain children who are 
allergic to cow’s milk report the same phenomenon.  
Fat globule  casein
 and  casein
Membrane protein
Whey protein
Homogenisation
 
Figure 6 Diagrammatic representation of milk homogenisation: large fat globules divide into smaller 
droplets, and proteins spread from micelles to cover the new fat droplets. 
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The hypothesis that might explain how milk homogenisation could cause symptoms is based 
on the fact that the composition of milk proteins is changed during homogenisation (Fig. 6). Raw 
cow’s milk contains lipid globules of different sizes (Ø 0.1 - 15 µm), which are covered by a phos-
pholipid layer and by membrane proteins. In raw milk, about 80% of the milk proteins are grouped 
in micelles. During homogenisation large lipid globules are broken up into smaller globules (Ø < 2 
µm). As a consequence, the surface area of the milk lipid globules expands and the membrane lay-
ers are no longer able to cover the fat globules and are thus partially replaced by milk proteins. In 
raw milk the majority of the antigenic determinants are inside the casein micelles, but in homoge-
nised milk the concentration of surface-exposed antigenic determinants is higher (Poulsen et al. 
1987). This change should not be of physiological significance, since the concentration of anti-
genic determinants in raw milk is high enough to produce reactions in people with cow’s milk pro-
tein allergy and antigenic determinants are not harmful to non-allergic people. 
Milk is heat-processed to destroy potential pathogens (Jensen 1995). Pasteurisation is a mild 
heating process (72°C, 15 seconds), and has a minimum effect on the structure and nutritional 
value of milk, but extends milk preservation time markedly. The ultra high temperature process is 
a strong heating process (140-150°C, 2 s), and it frees the milk of microbes. Pasteurisation at a 
high temperature (125-130°C, 0.5-2 s) is a new process for extending the milk’s preservation time, 
called the extended shelf life process, with a minimum effect on the organoleptic characteristics of 
milk. Heating processes have no effect on lactose composition, nor does heating milk remove or 
destroy the allergenic properties of milk protein. If one is considering using raw milk, one should 
take into account the fact that the microbial quality of raw milk may vary. Because of hygiene re-
quirements, the selling of raw milk is limited in the European Union (Council Directive 
92/46/EEC). 
There is some evidence from animal experiments that the processing of milk, i.e. homogenisa-
tion and pasteurisation, causes hypersensitivity reactions in study animals. In animal experiments, 
homogenised and pasteurised cow’s milk given orally to cow’s milk-sensitised mice induced ana-
phylactic shocks (Poulsen et al. 1987), increased IgE production (Nielsen et al. 1989), increased 
the production of milk-specific immunoglobulins, increased the mass of the gut segment and in-
duced degranulation of mast-cells (Poulsen et al. 1990), while unhomogenised pasteurised cow’s 
milk and unprocessed raw milk induced remarkably fewer symptoms and immunological re-
sponses, or none at all.  
However, there is no evidence that homogenisation of milk could cause more pronounced milk 
hypersensitivity in humans than unhomogenised milk. In clinical studies, no difference in toler-
ance between homogenised and unhomogenised cow’s milk has been observed, either in children 
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with CMA (Hansen et al. 1987, Høst et al. 1988) or in adults with lactose intolerance or milk hy-
persensitivity (Pelto et al. 2000). In a study by Høst et al. (1990) the maternal intake of homoge-
nised and unhomogenised milk did not affect the passage of bovine -lactoglobulin to breast milk 
in either atopic or non-atopic mothers. 
Some individuals who experience subjective milk-related gastrointestinal symptoms may actu-
ally be sensitive to substances in the diet other than lactose or cow’s milk protein. Some Finns 
report experiencing gastrointestinal symptoms comparable to those of lactose intolerance after 
consumption of Finnish milk, but abroad they are able to consume local dairy products without 
symptoms (Paajanen et al. 2004). The most commonly-used milk in Finland is homogenised, pas-
teurised low-fat milk (0.1-1.5% fat) (Männistö et al. 2003). As far as is known, no differences exist 
in the texture or processing of milk between Finland and other developed countries, which could 
explain the dissimilarity of symptoms. However, differences in the diet are likely to occur. The 
Finnish diet contains marked amounts of indigestible carbohydrates; for example, the average 
daily consumption of rye products high in indigestible fibre is 100 g in men and 66 g in women 
(Männistö et al. 2003). Indigestible carbohydrates, such as sweeteners (Born et al. 1994, Storey et 
al. 2002), fructo-oligosaccharides (Briet et al. 1995, Teuri et al. 1999) and galacto-
oligosaccharides (Teuri et al. 1998), have been found to induce symptoms similar to those of lac-
tose intolerance in some individuals, though not in all (van Dokkum et al. 1999, Moore et al. 
2003). According to Teuri et al. (1999), so-called pseudohypolactasic subjects mistakenly believe 
they have lactose intolerance, but are actually reacting to indigestible carbohydrates. We have 
studied the tolerance of indigestible carbohydrates in adults reporting better tolerance of milk 
abroad than in Finland, and have concluded that some individuals who report milk-related gastro-
intestinal symptoms may, in fact, be reacting to indigestible carbohydrates in the diet (Paajanen et 
al. 2004).  
The cause of gastrointestinal symptoms is often difficult to identify, and therefore diet restric-
tions should be conducted only after a thorough dietary and symptom follow-up. 
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AIMS OF THE STUDY 
 
The aim of this thesis was to study the effect of cow’s milk and its processing on symptoms and 
immune responses of delayed-type cow’s milk hypersensitivity. The specific aims were: 
 
• To study the effect of cow’s milk homogenisation on the symptoms of cow’s milk-
intolerant adults (I, II) and on the production of cow’s milk protein-specific antibodies in 
healthy adults (III) 
• To study intestinal immune activation in delayed-type CMA in children (IV, V) 
• To study the occurrence of milk-related reactions and subjective symptoms in relation to 
verified milk hypersensitivity in young adults (VI) 
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SUBJECTS AND METHODS 
 
1  SUBJECTS 
 
A summary of the study subjects is shown in Table 3. 
 
Studies I, II and III: Study I comprised 44 lactose-tolerant adults who had repeatedly experi-
enced better tolerance of unhomogenised than homogenised milk. In Study II, 87 adults, and 22 
children or the parents of these children, with subjective experience of a better tolerance of un-
processed milk than of processed, were interviewed. The first clinical part of Study II comprised 
15 lactose-intolerant adults, and the second, clinical part, 35 lactose-intolerant adults. The intoler-
ant subjects were recruited from our previous milk intolerance studies, from consumers who con-
tacted Valio Ltd Consumer Service, and from supermarkets (I, II). Study III comprised 36 adults 
with good tolerance of milk and a habit of daily milk consumption. 
 
Studies IV and V: The children in Studies IV and V had been referred to Oulu University Hospi-
tal, Finland, for a paediatric gastroenterological consultation because of recurrent gastrointestinal 
complaints. Study IV was made up of a heterogeneous group of 59 children with varying degrees 
of symptom density, whereas Study V comprised 26 children with unmistakable major symptoms. 
Children with negative cow’s milk and cereal challenges and normal endoscopic findings served as 
controls, and children with untreated celiac disease as disease controls for the children with de-
layed-type CMA.  
 
Study VI: In Study VI, a subgroup of a cohort of healthy children living in northern Finland, who 
had been gathered in 1994 for a study of risk factors for type 1 diabetes (n=3652, median age 12 y, 
range 7–16 y) was studied (Kulmala et al. 2001). Those subjects who had been drawn from four 
rural communities and were 16-21 years old were included in Study VI in 2002, making a total of 
1078 young adults. Of these, 26 were excluded because of biopsy-proven celiac disease (n=17), 
suspected celiac disease on the basis of elevated tissue transglutaminase (tTG) (n=7, 3 refused bi-
opsy confirmation, 4 were diagnosed as being healthy) or type 1 diabetes (n=2) (Kulmala et al. 
2001, Mäki et al. 2003). The address of 42 subjects was unknown, and therefore a postal question-
naire was mailed to 1010 young adults. In all, 827 subjects (82%) completed the form and made up 
the final study group. 86 subjects (10%, 11 male, 75 female) reported severe abdominal complaints 
(severe pain, persistent pain and/or pain combined with abnormal defecation functions); 49 of 
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these (4 male, 45 female) agreed to take part in a clinical examination and were examined by a 
paediatric gastroenterologist. Of those interviewed, 149 subjects (18%, 91 male, 58 female) had no 
history of gastrointestinal or allergic complaints and consumed milk daily, and 27 of these (12 
male, 15 female) were included in the study as healthy controls. Additional control subjects (n=10, 
2 male and 8 female, median age 16 y, range 14-18 y) were enrolled from outside the original 
study population, from among patients of Oulu University Hospital, to serve as controls for the 
endoscopic examination and the measurement of mucosal mRNA expression and intraepithelial T 
cell densities. The endoscopy controls were studied for prolonged gastrointestinal symptoms but 
had normal endoscopic findings and remained without any definite diagnosis. 
 
Table 3 Characteristics of the study subjects.  
Publication n Gender 
female/male 
Age, y 
mean (range) 
Description of study groups 
I 44 30/14 38 (18–64) Better tolerance of unhomogenised  
      than homogenised milk 
II     
Interview 22 
87 
5/17 
60/27 
5 (1–16) 
40 (18–75) 
Better tolerance of unhomogenised  
      than homogenised milk 
Intervention A 15 13/2 38 (25–62) Lactose-intolerant subjects 
Intervention B 35 32/3 30 (19–57) Lactose-intolerant subjects 
III 36 28/8 40 (19–62) Good tolerance of milk 
IV 59 31/28 10 (1–18) Delayed CMA (n=31), CD (n=14), 
       controls (n=14) 
V 26 18/8 10 (3–15) Delayed CMA (n=10), CD (n=6),  
       controls (n=10) 
VI     
Interview 827 460/367 18 (16–21) Major GI complaints (n=86),  
 minor GI complaints (n=316),  
 other symptoms (n=276),  
 no symptoms (n=149) 
Clinical examination 76 60/16 18 (16–21) GI symptoms (n=49), controls (n=27) 
Endoscopy 22 18/4 17  (14–21) GI symptoms (n=12), controls (n=10) 
CD, celiac disease; CMA, cow’s milk allergy; GI, gastrointestinal 
 
2  STUDY DESIGNS 
 
Studies I, II and III: In Studies I and II, the tolerance of different study milks was compared in 
randomised, double-blind, cross-over studies (Fig. 7). In Study I, two study milks were consumed, 
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each 2x200ml/d for five consecutive days: 1) pasteurised, unhomogenised milk (1.5% fat), and 2) 
pasteurised, homogenised milk (1.5% fat) with 20 ml/l of whipping cream added for blinding. 
In the first clinical part of Study II, three study milks were consumed, each 2 x 200ml/d, for 
four consecutive days: 1) unpasteurised, unhomogenised organically-produced full-fat milk, 2) 
pasteurised, homogenised full-fat milk, and 3) pasteurised, homogenised fat-free milk. In the sec-
ond part of Study II, two study milks were consumed, each 2 x 200ml/d, for two consecutive days: 
1) unpasteurised, unhomogenised organically produced full-fat milk, and 2) pasteurised, homoge-
nised full-fat milk. In Study II, a further 109 subjects were interviewed. 
In Study III, subjects were challenged for 28 days with both homogenised and unhomogenised 
cow’s milk and dairy products in a randomised, open, cross-over setting (>400 ml of milk daily). 
 
Study I   7-d baseline 5-d milk challenge 9-d wash-out 5-d milk challenge 
     
     
 
 
Study IIa 6-d base-
line 
4-d milk 
challenge 
10-d 
wash-out 
4-d milk 
challenge 
10-d 
wash-out 
4-d milk 
challenge 
6-d control
        
        
 
 
Study IIb 1-d baseline 2-d milk challenge 5-d wash-out 2-d milk challenge 
     
     
 
 
Study III 28-d milk challenge 28-d milk challenge 
   
   
 
Figure 7 Study designs of Studies I, II and III. 
 
Studies IV and V: In Study IV, the 59 patients underwent a gastroduodenoscopy performed by a 
paediatric gastroenterologist (Fig. 8). The cytokine release (IFN-, TNF-, TGF-, IL-2, IL-4, IL-
5, IL-6 and IL-10), histology and distribution of intraepithelial T cells were examined from intesti-
nal biopsy specimens.  
In Study V, six biopsies were taken from the bulb of the duodenum and six from the terminal 
ileum of ten children with delayed-type CMA and ten controls, and six duodenal biopsies were 
taken from six subjects with celiac disease. The cytokine mRNA expression (IFN-, TGF-, 
chemokine receptor CC (CCR-4), CCR-5, IL-2, IL-6, IL-10, IL-12p35, IL-12p40 and IL-18), his-
tology and distribution of intraepithelial T cells were examined from the biopsy samples. 
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Study IV
Study children
n=59
Delayed CMA,
consumed milk
n=17
Delayed CMA,
avoided milk
n=14
Celiac disease
n=14
Controls
n=14
Biopsies,
duodenum
n=17
Biopsies,
duodenum
n=14
Biopsies,
duodenum
n=14
Biopsies,
duodenum
n=14
 
 
Study V
Study children
n=26
Delayed CMA
n=10
Celiac disease
n=10
Controls
n=10
Biopsies,
duodenum
n=6
Biopsies,
IT
n=6
Biopsies,
duodenum
n=6
Biopsies,
IT
n=6
Biopsies,
duodenum
n=6
 
 
Study VI
Questionnaires
n=827
Controls
n=27
Symptomatic
subjects
n=47
Milk-soy challenge
n=27
Milk-soy challenge
n=23
Endoscopy 
n=10
Endoscopy controls
n=10
 
Figure 8 Study designs of Studies IV, V and VI. CMA, cow’s milk allergy; IT, ileum terminale 
 
Study VI: Study VI consisted of an interview, a food-use survey, a lactose maldigestion test, the 
genetic test of the C/T
-13910 variant associated with adult-type hypolactasia, a blinded milk-protein 
tolerance test, the measurement of antibodies to Helicobacter pylori, tTG and milk proteins, as 
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well as quantification of the plasma concentrations of soluble sICAM-1, and granzymes A and B, 
and in subjects with severe symptoms, an endoscopic examination and measurement of the muco-
sal mRNA expression of the following cytokines: IFN-, TNF-, IL-2, IL-4, IL-5 and IL-10. 
 
3  METHODS 
3.1  Questionnaires 
 
Subjects were interviewed about the presence of atopic diseases in each study (I-VI). The diagno-
ses of atopic manifestations (asthma, atopic dermatitis and allergic rhinitis) were based on general 
criteria and accepted only if made by a physician. 
The whole study population of Study VI was asked about the intensity and frequency of vari-
ous gastrointestinal symptoms, whether or not the symptoms were related to specific foods, about 
any atopic history, lactose intolerance and chronic diseases, and the use of milk and dairy products 
and other foods often related to gastrointestinal symptoms. Gastrointestinal symptoms were en-
quired about according to Rome II criteria for irritable bowel syndrome (Thompson et al. 1999). 
Both the symptomatic subjects and the controls in Study VI completed a food frequency ques-
tionnaire, concentrating on dairy product consumption and calcium intake, modified from a form 
validated by Dr. Sulin Cheng and Dr. Arja Lyytikäinen et al. (Calex-study, Jyväskylä, Finland, 
unpublished data 1998).   
In Study VI, the parents of the symptomatic subjects and of the controls completed a semi-
structured form, also used in a former study (Kokkonen et al. 2004), which included questions 
regarding the first years of life of the study children, such as the length of time of breast feeding 
and whether food hypersensitivities, excessive crying, vomiting/regurgitation, or any other gastro-
intestinal symptoms or allergic symptoms were manifested. Any gastrointestinal and allergic dis-
eases of the parents were also enquired about. 
The questionnaires used were pre-tested for clarity on volunteers who belonged to the same 
age group as the study subjects.  
 
3.2  Investigation of adverse reactions to cow’s milk 
 
Assessment of symptoms related to homogenisation of cow’s milk 
In Study II, symptoms related to the ingestion of homogenised and unhomogenised milk were ret-
rospectively enquired about by means of a semi-structured form. In Studies I and II, the sympto-
matic response to unhomogenised and homogenised milk was investigated. During the blinded 
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challenges with the study milks and also during the breaks, the subjects kept a daily record of the 
consistency and number of their bowel movements, abdominal symptoms, compliance with the 
milk-free diet, and study drink consumption.  
In Study I, the subjects ranked daily each gastrointestinal symptom from no symptoms (0) to 
very severe symptoms (3); the possible range of symptoms was 0-60 points over the 5-day chal-
lenge. In Study II, the subjects indicated the severity of gastrointestinal symptoms and hardness of 
faeces, graded from no symptom / very hard faeces (0 mm) to very severe symptoms/very loose fae-
ces (100 mm), by indicating each symptom on a 100 mm-long straight visual analogue scale line; 
the possible daily range of the sum of symptoms was 0-300 mm in part IIa, and 0-400 mm in part 
IIb. 
 
Assessment of symptoms related to cow’s milk protein 
Cow’s milk protein hypersensitivity was determined in Studies IV-VI. In Studies IV and V, the 
diagnosis of hypersensitivity to cow’s milk was based on the disappearance of symptoms during 
the cow’s milk elimination diet (4 weeks) and their reappearance in an open challenge test, which 
was to continue for another 4 weeks with low lactose cow’s milk and dairy products if symptoms 
did not reappear earlier. Those children who were suspected of reacting to both cow’s milk and 
cereals also took part in an open cereal challenge in which the diagnosis of hypersensitivity to ce-
reals was based on the disappearance of symptoms during the cereal elimination diet (4 weeks) and 
their reappearance in an open challenge test, which was to continue for another 4 weeks with wa-
ter-based porridge and wheat bread if symptoms did not reappear earlier. As part of the clinical 
treatment of the study children, either the children or their parents filled in daily a questionnaire on 
symptoms (abdominal pain, diarrhoea, loose mucous stools and dermatitis) and on milk ingestion 
during the open milk elimination-challenge procedure. Because the patients were late-onset re-
sponders, the gold standard, a blinded challenge, was considered too laborious for clinical work. 
In Study VI the milk protein tolerance of symptomatic subjects was investigated in a double-
blind placebo-controlled food challenge consisting of a 3-week placebo soy drink challenge, a 3-
week milk protein challenge blinded with the same soy drink, in randomised order, and a 1-week 
wash-out period preceding each drink challenge. The subjects were on a milk-free diet during the 
eight weeks of the placebo-controlled food challenge. They kept a record of the intensity of vari-
ous gastrointestinal symptoms graded from no symptoms (0) to very severe symptoms (4), of 
compliance with the milk-free diet, and consumption of the study drink during the 8-week double-
blind place-controlled food challenge. The possible daily range of the sum of symptoms was 0-20 
points. 
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Lactose maldigestion 
The methods used for the assessment of lactose maldigestion and hypolactasia are summarised in 
Table 4. Subjects with hypolactasia were diagnosed as lactose intolerant according to their symp-
tomatic responses, monitored by written symptom records (I, II, VI).  
 
Table 4 Methods used for assessment of lactose maldigestion and hypolactasia. 
Method Original publication 
Lactose maldigestion tests  
Hydrogen breath test I, II 
Methane breath tests II 
Alcohol-galactose test VI 
Conventional glucose test     IV-VI 
Symptom records I, II, VI 
Test for hypolactasia  
Genetic test of C/T
-13910 VI 
 
In Study I, the digestion of lactose was determined by a 3-hour hydrogen breath test. After an 
overnight fast, the subjects ingested 25 g of lactose dissolved in 300 ml of water and flavoured 
with 1 ml of unsweetened juice, and breath hydrogen was measured twice an hour with a Micro 
H2 Meter (Micro Medical, Kent, UK). In Study II, after an overnight fast, the subjects ingested 
50 g of lactose dissolved in 250 ml of water and flavoured with 1 ml of unsweetened juice, and 
breath hydrogen and methane were measured twice an hour for three hours with a Quintron Model 
DP Microlyzer (Quintron Instrument Co, Milwaukee, WI, USA). An increase in breath hydrogen 
of  20 ppm was considered hypolactasia (I, II). 
In Study VI, an alcohol-galactose test was used (Isokoski et al. 1972), with modifications as 
reported by Pelto et al. (2000): the subjects ingested 50 g of lactose with 150 mg/body kg of alco-
hol after an overnight fast, the serum galactose was determined after 40 minutes (Galac, Roche 
Diagnostics, Basel, Switzerland), and a serum galactose level of less than 0.2 mmol/l was consid-
ered hypolactasia. The lactose absorption of seven subjects in Study VI whose religious beliefs 
forbade the consumption of alcohol, as well as the patients of Studies IV and V who were sus-
pected of being lactose intolerant, was determined after an overnight fast by serial (0, 20, 40 and 
60 min) glucose measurements (Glucose HK Liquid, Roche Diagnostics) following a 50 g lactose 
load. A difference of 1.1 mmol/l or less between the lowest and the highest measurements was 
considered hypolactasia. In addition, in Study VI the subjects were genotyped for the C/C
-13910 
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variant of lactase persistence/nonpersistence (adult-type hypolactasia) (Enattah et al. 2002, Kuok-
kanen et al. 2003, Rasinperä et al. 2004). 
 
3.3 Immunological investigations 
 
The immunological investigations carried out in this thesis are summarised in Table 5. The sub-
jects of Study VI were previously analysed for the HLA-DQ2 molecule encoding genes in order to 
examine susceptibility to celiac disease and other autoimmune diseases (Mäki et al. 2003), and 
these data were utilised in Study VI. Samples were analysed, by using a screening test, for selected 
HLA-DQB1 alleles, including DQB1*02 and DQB1*0302, and samples that were positive for the 
HLA-DQB1*02 allele were further analysed for the presence of associated alleles, HLA-
DQA1*0201 and DQA1*05. 
 
Table 5 Immunological investigations. 
Method Publication 
Antibody measurements  
ELISA: Cow’s milk protein specific antibodies III, VI 
ELISA: specific IgA antibodies against tTG IV-VI 
Enzyme immunoassay: specific IgG antibodies against H. pylori VI 
Local immunological measurements from biopsy specimens/biopsy supernatants  
ELISA: TGF- and IL-6 IV 
Cytometric bead array: IFN-, TNF-, IL-2, IL-4, IL-5 and IL-10 IV 
rt-PCR: IFN-, TGF-, CCR-4, CCR-5, IL-2, IL-6, IL-10, IL-12p35,  
              IL-12p40 and IL-18 
V 
rt-PCR: IFN-, TGF-, IL-6, IL-12p35 and IL-18 VI 
Systemic immunological measurements from plasma  
ELISA: sICAM-1, granzymes A and B VI 
Cytometric bead array: IFN-, TNF-, IL-2, IL-4, IL-5 and IL-10 VI 
Endoscopic examination and assessment of biopsy specimens  
Assessment of lymphoid nodularity IV-VI 
Histology, villus atrophy IV-VI 
Densities of intraepithelial lymphocytes IV-VI 
ELISA, enzyme linked immunosorbent assay; CCR, chemokine receptor CC; H. pylori, Helicobacter py-
lori; IFN-, interferon ; Ig, immunoglobulin; IL, interleukin; rt-PCR, real-time polymerase chain reaction; 
sICAM-1, soluble intercellular adhesion molecule 1; TGF-, transforming growth factor ; tTG, tissue 
transglutaminase; TNF-, tumor necrosis factor  
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Antibody measurements 
In Study III, the presence of casein-, -lactoglobulin- and bovine insulin-specific IgG and IgA, 
and casein-specific IgE, and in Study VI, the presence of casein and -lactoglobulin-specific IgG 
and IgA in plasma was measured by ELISA assays. Microplates were coated with various antigens 
at a concentration of 1 µg/ml of buffer (0.2% human serum albumin - phosphate-buffered saline + 
0.05% Tween), and blocked with 1% human serum albumin. 100 µl of diluted (from 1:10 to 1:50) 
samples were pipetted into the wells. The IgG antibodies present were bound with diluted rabbit 
anti-human IgG (Jackson Immuno Research Inc, West Grove, PA, USA), and the IgA and IgE 
antibodies, by using biotinylated goat anti-human IgA or IgE (Vector Laboratories Inc, Burin-
game, CA, USA) and AP Streptavidin (Zymed laboratories, Carlsbad, CA, USA). The reaction 
was developed by adding phosphate substrate tablets. Optical densities were read at 405 nm for 
0.1 s with a multilabel counter (1420 Victor2, Wallac, Turku, Finland). The results were expressed 
as optical density units, and these units were considered the relative amounts of the antibodies. All 
reagents, other than those mentioned above, were from Sigma-Aldrich Co, St. Louis, MO, USA. 
 In Studies IV-VI, serum IgA-class antibodies to tTG were measured by an ELISA method, and 
in Study VI serum IgG-class antibodies to Helicobacter pylori by an enzyme immunoassay 
method (Pyloriset EIA-G III, Orion Diagnostica, Espoo, Finland). 
 
Measurement of cytokines, chemokine receptors and granzymes 
In Studies IV and VI, commercial ELISA kits were used for the analysis of TGF-1 (Quantikine®, 
R&D Systems Inc, Minneapolis, MN, USA, Study IV), IL-6 (PeliKine CompactTM, Central Labo-
ratory of the Netherlands Red Cross, Amsterdam, Netherlands, Study IV), sICAM-1 (HyCult Bio-
technology, Uden, Netherlands, Study VI) and granzymes A and B (Sanquin, Amsterdam,  Nether-
lands, Study VI), and cytometric bead array human Th1/Th2 kit (BD Biosciences, San Diego, CA, 
USA) for the analysis of certain cytokines (IV, VI). 
In Studies V and VI, the expression of certain cytokines and chemokine receptors was meas-
ured by real-time quantitative reverse transcriptase polymerase chain reaction (rt-PCR). Total 
RNA was extracted from frozen biopsies by RNA Total Gen Elute Mammalian RNA kit (Sigma-
Aldrich Co). Reverse transcription reaction was carried out by using TaqMan Reverse Transcrip-
tion Reagents (all rt-PCR reagents from Applied Biosystems, Foster City, CA, USA). The PCR 
was performed in triplicate wells using TaqMan pre-developed assay reagent universal MasterMix, 
1 x pre-developed assay reagent primers/probes, and template cDNA, and measured with an auto-
mated fluorometer, the ABI-Prism 7700 Sequence Detection System (Applied Biosystems). Ribo-
somal 18S was used as an endogenous control. The expression of each cytokine was also measured 
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from a home-made calibrator sample, which was prepared from the phytohemagglutinin-
stimulated peripheral blood mononuclear cells of a healthy subject. The comparative threshold 
method was used to quantitate the gene transcription in the samples. To obtain the whole numbers 
for plots, the relative numbers were multiplied by 100, excluding IL-18, whose numbers were not 
multiplied.
 
 
Endoscopic examination and assessment of biopsy specimens 
The subjects of Studies IV, V and VI who had persistent gastrointestinal symptoms were studied 
by endoscopy. Endoscopies were carried out before any food challenges. Gastro-duodenoscopies 
were performed with an Olympus CIF-IT140 (Olympus, Tokyo, Japan), and colonoscopies with an 
Olympus GF Q1401 (Olympus), both under general anaesthesia. 
The assessment of lymphoid nodularity on the mucosa of the duodenum and/or ileum was 
based on endoscopic evaluation after filling the area to be inspected with air. Only a cluster of 
lymphoid nodules (n>10 nodules) was considered significant. The criteria used to assess the sever-
ity of LNH were: grade 0, no lymphoid follicles present; grade 1, mild to moderate LNH, small 
lymphoid follicles dispersed on the walls; and grade 2, severe LNH, massed with lymphoid tissue. 
For histopathology, the biopsy specimens were fixed in formalin, embedded in paraffin, and 
stained with hematoxylin and eosin. The lengths of crypt and villi were measured with an ocular 
micrometer. 
For immunohistochemical stainings, biopsy samples were stained, and the numbers of lym-
phocytes were counted per mm of epithelium under a light microscope with a 100x flat field objec-
tive. 20-30 fields (1-1.5 mm) were examined for the presence of CD3+ T lymphocytes and  and 
 TCR-bearing intraepithelial lymphocytes. 
 
3.4  Statistical analyses 
 
The following analyses were performed to estimate the significance of the differences between the 
cross-over milk challenges: the analysis of variance (ANOVA) for repeated measurements was 
used to study treatment, period and carry-over effects (I–III); the Wilcoxon test, to compare the 
intensity of the symptoms (II); the non-parametric McNemar, to compare the prevalence of symp-
toms between the study challenges (I, II); and because significant period and carry-over effects 
were found, Fisher’s exact test was also utilised in Study II.  
Differences between the patient groups were determined with: the one-way ANOVA with a 
post hoc test (IV); the independent samples t test (VI); and in the case of limited data, the non-
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parametric Mann-Whitney U-test and the Kruskall Wallis test (V). Dichotomous variables were 
tested with the Pearson Chi-Square test (V, VI) and correlations with the Pearson correlation coef-
ficient (IV). The 95% confidence intervals (CI95) for the prevalence of symptoms were tested with 
the normal distribution approximation or, in the case of small sample size (n<50), by the exact 
method based on binomial distribution (VI).  
In the cases of skewed data, logarithmic (ln) transformation was used if parametric analyses 
were performed (III, IV, VI). Depending on the number of the subjects and the skewness of the 
data, means are presented with SEM (I) or with CI95 (VI), geometric means with CI95 (III), and 
medians with ranges (II, IV, V).  
Data were analysed using SPSS software (SPSS Inc, Chigago, IL, USA). A p value of <0.05 
was considered significant. 
 
4  ETHICS 
 
The study protocols of Studies I and III were approved by the Ethics Committee of the Hospital 
District of Helsinki and Uusimaa, that of Study II by the Ethics Committee of the Foundation for 
Nutrition Research, and those of Studies IV, V, and VI by the Ethics Committee of Oulu Univer-
sity Hospital. Informed, written consent was obtained from the study subjects (I-III, VI) and/or the 
parents of the study children (IV, V). 
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RESULTS 
 
1 EFFECT OF MILK HOMOGENISATION ON SYMPTOMS AND ON ANTIBODY 
RESPONSE TO MILK 
1.1  Symptoms related to milk homogenisation (I, II) 
 
In an interview, subjectively milk-intolerant subjects mainly reported gastrointestinal symptoms 
related to the intake of processed milk (II). However, in the blinded challenges, the homogenised 
and unhomogenised milks produced equal symptoms in subjects subjectively sensitive to homoge-
nised milk (I) as well as in those who had been diagnosed as lactose intolerant (II). 
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Figure 9 Symptoms reported as being caused by homogenised milk by 109 subjects interviewed, subjec-
tively intolerant to homogenised milk. Symptoms are expressed as percentage of subjects with 
95% confidence interval (II). *Swelling and rumbling of the stomach. 
 
Questionnaire 
The subjectively milk-intolerant subjects interviewed in Study II for the most part reported gastro-
intestinal symptoms related to the intake of processed milk, though skin or other symptoms were 
occasionally mentioned (Fig. 9). Gastrointestinal symptoms appeared during the 12 h following 
milk ingestion in all the subjects, while skin symptoms took up to 3 days to appear (Fig. 10A). In 
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most cases (84% of the subjects) the symptoms disappeared within 24 h of the termination of milk 
ingestion; skin symptoms were the slowest to fade (Fig. 10B). 
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Figure 10 A. Time to symptom manifestation (123 answers), and B. length of symptomatic period after 
ingestion of homogenised milk (122 answers) as reported by 109 subjects subjectively intoler-
ant to it (II). Some subjects reported different times for different symptoms. 
 
Most subjects (81%) reported no symptoms from unhomogenised milk, a few (8%) reported 
weaker symptoms from unhomogenised than from homogenised milk, and some (7%) reported 
that unhomogenised milk also occasionally induced symptoms. 41% of the subjects had tried a 
totally milk-free diet, during which they had experienced no symptoms at all. 26% were diagnosed 
as suffering from lactose intolerance, 4% irritable bowel syndrome, and 2% celiac disease. 
The unhomogenised milk most commonly used by the subjects was a commercial, organically 
produced, pasteurised, unhomogenised milk (103 subjects); 18 subjects had consumed unpasteur-
ised, unhomogenised farm milk. Unhomogenised milk was drunk without symptoms by 77% of 
the subjects, while the rest used it only in cooking. Most of the subjects were able to consume cer-
tain dairy products without suffering any symptoms (Fig. 11), and many subjects (46%) were able 
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to consume small amounts of homogenised milk as an ingredient in cooking. Dose-response was 
mentioned by 76% of the subjects.  
 
0% 20% 40% 60% 80% 100%
Other dairy products, H
Ice cream, H
Piimä (fermented milk drink), H
Yoghurt, H
Milk chocolate, H
Viili (fermented milk dessert), UH
Low-lactose products, UH/H
Organic yoghurt, UH
Butter, UH
Cheese, UH
% of the subjects
Tolerated
Not tolerated
Don't know
 
Figure 11 Milk products reported as being tolerated or otherwise by subjects interviewed, who were sub-
jectively intolerant to homogenised milk (n=109, II). UH, unhomogenised; H, homogenised 
 
Challenges with unhomogenised and homogenised milk 
The symptomatic responses of the subjects were observed during challenges with unhomogenised 
and homogenised milks (Studies I and II). There was no difference between the effect of homoge-
nised and unhomogenised milk on the severity or the prevalence of the symptoms in either of these 
two studies. The symptom scores are summarised in Figure 12. In Study I, the difference between 
the scores of the homogenised and the unhomogenised milk during the 5-day milk challenges was 
0.9 points (CI95 -2.4–4.2) (p=N.S., theoretical max. symptom score 60 points). In Study IIa, based 
on the period averages, the median sum of gastrointestinal symptoms was 74 mm (range 0–185) 
for unprocessed milk, 51 mm (9–117) for processed full-fat milk and 90 mm (22–167) for proc-
essed fat-free milk (p=N.S. for all, theoretical max. score 300 mm). In Study IIb, based on the 
period averages, the median sum of gastrointestinal symptoms was 60 mm (range 0–280) for un-
homogenised and 55 mm (0–290) for homogenised milk (p=N.S., theoretical max. score 300 mm). 
The median stool characteristics and number of stools remained constant during Studies I, IIa and 
IIb. 
Even though in general unhomogenised milk was not better tolerated, in Studies I and IIb, two 
subjects tolerated it markedly better. In Study I, one of the two had 40 points more symptoms dur-
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ing the unhomogenised than during the homogenised milk period, and the other, 20 points more 
symptoms, the maximum symptoms per milk period being 60 points. In Study I, two subjects gave 
up homogenised milk and one subject gave up unhomogenised milk, because of severe reactions. 
In Study IIb, two subjects stopped drinking the processed milk after the first test day, because of 
very loose stools and other severe symptoms. 
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Figure 12 Median symptom scores as percentages of the theoretical maximum symptom score during 
challenges with unhomogenised milk (UM) and homogenised milk (HM). Study I comprised 
subjectively milk-intolerant subjects (n=44) and Studies IIa (n=15) and IIb (n=35), lactose-
intolerant subjects. 
 
In Studies I and IIb, the severity and prevalence of symptoms were higher during the milk 
challenges than during the milk-restricted run-in period. In Study IIa, the prevalence of flatulence 
and abdominal bloating, to at least a moderate degree, was high during all three milk periods, and 
even during the low-lactose control periods.  
In Study I, the subjects experienced more symptoms (mean 10.8 points, CI95 8.4–13.2) during 
the second challenge than during the first (7.0 points, CI95 4.5–9.5), regardless of the order in 
which they received the different types of milk (period effect p=0.02). However, the sum of symp-
toms was similar during the run-in period and the wash-out period between the challenges. Some 
carry-over and period effect also affected the milk periods of Study IIb. The subjects experienced 
more symptoms during the first period (median 85 mm) than during the second (45 mm), inde-
pendent of which milk was ingested (period effect p=0.002), but the carry-over effect was non-
significant (p=0.72). In particular, abdominal pain and bloating were more common during the 
first milk period (66% and 83% respectively) than during the second milk period (40% and 63%) 
(period effect for abdominal pain p=0.05 and for bloating p=0.07, and carry-over effect for ab-
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dominal pain p=0.05). When the period effect was eliminated by only taking into account the first 
period, there was a tendency towards a smaller number of symptomatic subjects during the un-
processed compared to the processed milk period (for pain 53% vs. 78%, p=0.16, and for bloating 
71% vs. 94%, p=0.09). 
 
1.2  Effect of milk homogenisation on antibody production (III) 
 
In Study III, IgG and IgA against casein, -lactoglobulin and bovine insulin, and IgE against ca-
sein were measured by ELISA from serum samples taken from 36 milk-tolerant adults at baseline 
and at the end of the 28-d-long challenges with homogenised and unhomogenised cow’s milk. The 
antibody production of the subjects remained constant, with no differences between the challenges 
with the two milks (Fig. 13). Inter-individual variation was notably greater than intra-individual or 
the variation between the milk challenges, as seen in Figure 14. The order of the milk challenges 
did not affect the results.  
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Figure 13  Relative amounts of antibodies studied, at baseline and during the challenges with homoge-
nised and unhomogenised milk (geometric mean ± 95% CI, n=36). Cas, casein; Ig, immu-
noglobulin; BLG, -lactoglobulin; Ins, insulin 
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Figure 14  Production of casein-specific immunoglobulin (Ig) G by each study subject, at baseline and 
after challenges with unhomogenised and homogenised milk, showing that individual antibody 
production of the subjects remained constant over the challenges (n=36). Each line represents 
one subject. 
 
2 INTESTINAL IMMUNE ACTIVATION IN DELAYED-TYPE COW’S MILK AL-
LERGY, AND IN IMMUNE-LIKE GASTROINTESTINAL SYNDROME 
2.1  Endoscopic findings, histopathology and intraepithelial lymphocytes (IV-VI) 
 
In Studies IV and V, lymphonodular hyperplasia of the duodenal bulb or terminal ileum was a 
characteristic endoscopic finding in most of the children with delayed CMA, though not in all (Ta-
ble 6). In Study VI, none of the young adults with gastrointestinal symptoms or the controls 
showed lymphonodular hyperplasia. Only the celiac disease cases showed duodenal villous atro-
phy or crypt hyperplasia. 
In the duodenal samples, the densities of intraepithelial T cells were slightly up-regulated in 
those children with delayed CMA who were exposed to dietary cow’s milk (IV, V), and in young 
adults with gastrointestinal symptoms (VI) (Table 7, Fig. 15). The children with celiac disease had 
by far the highest densities of CD3+, + and + T-cells in the duodenum compared to any other 
group (p<0.001 for all, IV, V), while densities were normal in the controls (IV-VI). These results 
show an up-regulation of duodenal intraepithelial T cells in untreated food hypersensitivity. In 
fact, in Study IV, densities were normal in those children with CMA who avoided cow’s milk. 
Densities of intraepithelial lymphocytes in the terminal ileum are presented in Figure 16. 
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Table 6  Lymphonodular hyperplasia (LNH) found in the bulb of the duodenum or the terminal ileum in 
the study groups. Figures represent numbers of LNH subjects out of total group numbers. 
 LNH of duodenum LNH of ileum     
Study IV    
Delayed CMA 17/33 no samples 
Celiac disease 1/17 no samples 
Controls 0/14 no samples 
Study V   
Delayed CMA 3/6 6/6 
Celiac disease 0/6 no samples 
Controls 0/6 0/6 
Study VI   
GI symptoms 0/8 0/7 
Controls 0/8 0/6 
CMA, cow’s milk allergy; GI, gastrointestinal 
 
Table 7 Up-regulation of intraepithelial lymphocytes in children with delayed cow’s milk allergy 
(CMA, IV, V) and young adults with immune-like gastrointestinal syndrome (VI). P-values 
compared to the controls are presented as follows: (*)p<0.065, *p<0.05, **p<0.01.  
 CMA1, IV CMA2, IV CMA1, V GI syndrome, VI 
Biopsies from duodenum     
CD3
+
 
*   (*) 
αβ+ ** * (*)  
γδ+     
γδ+/CD3+     
Biopsies from ileum     
CD3
+
 
no samples no samples   
αβ+ no samples no samples   
γδ+ no samples no samples *  
γδ+/CD3+ no samples no samples (*)  
 increased,  stable  
CMA1, children with delayed CMA who consumed cow’s milk; CMA2, children with delayed CMA who 
avoided cow’s milk; GI syndrome, young adults with immune-like gastrointestinal syndrome 
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Figure 15  Densities of intraepithelial CD3+, +, + T cells and +/CD3+ ratio in the bulb of the duo-
denum, presented as box-plot figures (IV-VI). Boxes represent the 95% confidence intervals 
with medians, vertical lines represent ranges, and outliers are marked as circles. The study 
groups are labelled as follows: Study IV: CMA1, children with delayed cow’s milk allergy who 
consumed milk; CMA2, children with delayed CMA who avoided milk; CD, celiac disease; 
Ctrl, controls. Study V: CMA, delayed CMA; CD, celiac disease; Ctrl, controls. Study VI: GI 
sympt, subjects with GI symptoms (immune-like GI syndrome); Ctrl, controls. 
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Figure 16  Densities of intraepithelial CD3+, +, + T cells and +/CD3+ ratio in the terminal ileum, 
presented as box-plot figures (V-VI). Boxes represent 95% confidence intervals with medians, 
vertical lines represent ranges, and outliers are marked as circles. The study groups are labelled 
as follows: Study V: CMA, delayed cow’s milk allergy; Ctrl, controls. Study VI: GI sympt, 
subjects with GI symptoms (immune-like GI syndrome); Ctrl, controls. 
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showed lower secretion of TGF- than those with delayed CMA who avoided cow’s milk (399.5 
vs. 612.3 pg/ml, p=0.050), a tendency towards lower secretion of TGF- than the controls (399.5 
vs. 441.1 pg/ml, p=0.078), and slightly higher secretion of IL-4 (5.5 vs. 2.7 pg/ml, p=0.016) and 
IL-10 (4.6 vs. 2.8 pg/ml, p=0.059). 
In Study V, the children with delayed CMA expressed less IL-2 and IL-18 mRNA in the duo-
denum (median 0.78 vs. 2.22, p=0.055; 54.28 vs. 239.87, p=0.055), and more CCR-4 and IL-6 
mRNA in the terminal ileum (22.39 vs. 9.60, p=0.055; 0.57 vs. 0.12, p=0.016) than the controls. 
The mRNA expression levels of the regulatory cytokines, TGF-β and IL-10, remained similar in 
all three groups.  
 
Table 8 Activation of cytokines, chemokine receptors and granzymes in children with delayed CMA 
(IV, V) and young adults with immune-like gastrointestinal syndrome (VI). P-values compared 
to the controls are presented as follows: (*)p<0.065, *p<0.05, **p<0.01, ***p<0.001.  
 CMA1, IV CMA2, IV CMA1, V GI syndrome, VI 
Biopsies from duodenum     
IFN- ** *   
TGF- 	(*)    
IL-2   	(*)  
IL-4 *  not studied not studied 
IL-10 (*)    
IL-18 not studied not studied 	(*)  
Biopsies from ileum     
IL-6 no samples no samples *  
CCR-4 no samples no samples (*) not studied 
Blood samples     
sICAM-1 not studied not studied not studied ** 
Granzyme-A not studied not studied not studied 	*** 
 increased; 	 decreased;  stable  
CMA1, children with delayed cow’s milk allergy who consumed cow’s milk; CMA2, children with delayed 
CMA who avoided cow’s milk; GI syndrome, young adults with immune-like gastrointestinal syndrome, 
and; CCR, chemokine receptor CC; IFN-, interferon ; IL, interleukin; sICAM-1, soluble intercellular 
adhesion molecule 1; TGF-, transforming growth factor  
 
2.3  Immune profile in immune-like gastrointestinal syndrome (VI) 
 
In Study VI, the symptomatic subjects (n=8) studied by endoscopy tended to express slightly more 
TGF- mRNA (3.3 vs. 1.0, p=0.073) and IL-12p35 mRNA (26.5 vs. 13.6, p=0.075) in the duode-
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nal biopsy samples than the controls (n=8). The symptomatic subjects (n=47) had higher mean 
plasma concentrations of sICAM-1 (71.4 vs. 57.8 ng/ml, p=0.008) and lower plasma concentra-
tions of Granzyme A (29.6 vs. 56.0 pg/ml, p=0.001) than the controls (n=27). In systemic immune 
defence, i.e. cytometric bead array analysis of the plasma cytokine concentrations, no differences 
between the groups were found. 
 
3  GASTROINTESTINAL DISORDERS IN YOUNG ADULTS 
3.1  Gastrointestinal symptoms and diseases in young adults (VI) 
 
In a population-based survey (VI), about half the 827 subjects (n=402, 49%) reported having had 
one or more abdominal complaints during the previous year, in 316 the symptoms being minor and 
in 86, major. 43 subjects (5.2%) fulfilled the Rome II criteria for irritable bowel syndrome. Gastro-
intestinal symptoms were far more frequent among the females than among the males: in the group 
with major gastrointestinal symptoms, 87% (75/86) were female compared to 39% (58/149) in the 
healthy group (p<0.001). 
Of the 86 subjects with major gastrointestinal symptoms who were interviewed, 49 agreed to 
undergo clinical examination. Ten of these (20%) had elevated serum IgE (median 204, range 115-
2222 IU/l). One subject was positive for IgA antibodies towards tTG, was diagnosed by gastro-
scopy as having celiac disease, and excluded from further immunological measurements. One sub-
ject was diagnosed as having ulcerative colitis, and was also excluded from further immunological 
measurements. Of the symptomatic subjects, 3 (6%) were positive for IgG-class Helicobacter py-
lori antibodies as were 3 (11%) of the healthy controls.  
 
3.1  Tolerance of milk in young adults (VI) 
 
In the questionnaires (n=827), 13.1% reported that they suffered from lactose intolerance. In the 
clinical examination, the lactose maldigestion test was positive in 16 of the 47 symptomatic sub-
jects (34.0%). However, only four (8.5%) had the C/C
-13910 genotype associated with adult-type 
hypolactasia and the rest carried the C/T
-13910 genotype of lactase persistence. Out of 27 symptom-
free controls, one (3.7%) had the C/C
-13910 genotype of adult-type hypolactasia, 15 (55.5%), the 
C/T
-13910, and 11 (40.7%), the T/T-13910 genotype of lactase persistence.  
The symptomatic subjects had lower concentrations of casein-specific IgG than the controls 
(n=47 vs. n=27; 0.91vs. 1.20; mean diff. 0.28, CI95 0.01–0.57; p=0.043). The difference was great-
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est between those symptomatic subjects who did not drink milk and the controls (n=31 vs. n=27, 
0.83 vs. 1.20; mean diff. 0.37, CI95 0.05–0.68; p=0.023).  
In the blinded cow’s milk-protein challenge, the cow’s milk and the placebo soy drink pro-
voked equal symptoms (mean difference -0.34, CI95 -7.1–6.4, p=0.920). Of the 23 symptomatic 
subjects who completed the challenge, 16 experienced intense gastrointestinal symptoms during 
both the milk and the placebo soy challenges, five experienced more symptoms (>10 points/week) 
during the 3-week low-lactase milk challenge, and nine during the 3-week placebo soy challenge, 
while in nine no difference was observed between the challenges. Only two subjects had severe 
and permanent symptoms during the milk challenge, and one of these was lactose intolerant. 
Among the 25 non-symptomatic controls who completed the challenge, one experienced some 
gastrointestinal symptoms during the milk challenge, and one other, during the soy challenge. The 
theoretical maximum sum of gastrointestinal symptoms was 140 points/week. 
In the questionnaires, 109 of the 827 (13.2%, CI95 10.9–15.5%) reported that they did not drink 
milk – this was more common in the females (86/458, 18.8%) than in the males (23/369, 6.2%, 
p<0.001), and in the group with major gastrointestinal symptoms (31/86, 36.0%) than in all the 
other subjects together (78/741, 10.5%, p<0.001). Those with major gastrointestinal complaints 
reported more food-related symptoms than did all the other subjects (p<0.001), and reported more 
abdominal pain (n=55, 64%), diarrhoea (n=27, 31%), constipation (n=9, 11%) and skin symptoms 
(n=3, 4%) related to milk ingestion. Abdominal pain was commonly reported after ingestion of all 
foods enquired about, including non-dairy products. In the food usage frequency form, it was seen 
that the symptomatic study subjects restricted their diet in various ways compared to the healthy 
controls. 
None of the symptomatic subjects who were clinically examined reported that they eliminated 
all dietary cow’s milk proteins, either at the time of the interview or previously. However, avoid-
ance of milk and/or dairy products was common, since only 14 (29%) consumed such products 
without restriction. 
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DISCUSSION 
 
1  METHODOLOGICAL ASPECTS (I-VI) 
 
Selection of study subjects  
Studies I-III: The tolerance of homogenised and unhomogenised/unprocessed cow’s milk was 
compared in two studies, in three different settings, and no differences in the symptoms during the 
challenges with homogenised and unhomogenised milk were discerned (I, II). Nor, in Study III, 
did antibody production by milk-tolerant adults differ between the challenges with homogenised 
and unhomogenised milk. The subjects of Study I had subjectively experienced better tolerance of 
unhomogenised than homogenised milk, and the subjects of Study II were lactose-intolerant vol-
unteers. Even though it would have been interesting, it was not possible in Study III to study milk-
intolerant subjects since they are not able to consume milk long enough to induce alterations in 
antibody levels, as far as non-IgE-mediated reactions are concerned. 
 
Studies IV-VI: To obtain an objective view of intestinal changes in delayed-type CMA, these 
were examined in study populations differing from each other (IV-VI). In Studies IV and V, both 
the subjects and the controls had been referred to Oulu University Hospital for gastroenterological 
consultation because of recurrent gastrointestinal complaints. In Study IV, all those patients diag-
nosed as having delayed-type CMA or celiac disease were included. On the other hand, only well-
defined controls and those with major symptoms of delayed-type CMA or celiac disease were in-
cluded in Study V, and therefore the subjects were more homogeneous than the subjects of the 
previous study. For Study VI, symptomatic young adults were selected for endoscopy from a 
population-based cohort. Many of them suspected that milk was the cause of their symptoms, but 
in a blinded milk challenge their symptoms were found not to relate to milk. It is not unexpected 
that cytokine results and endoscopic findings differed between the study populations since there 
was distinct symptomatic heterogeneity of the three populations. However, the densities of intra-
epithelial lymphocytes were up-regulated and found to be fairly similar in all these groups. 
In Studies IV-VI, children with negative challenges to cow’s milk and cereal and with normal 
endoscopic findings served as controls, since the cause of their gastrointestinal complaints were 
considered to be of psychological origin. As far as children are concerned, the indication for inva-
sive gastro-/colonoscopia has to be clinical, and symptom-free healthy controls cannot be used 
because of ethical considerations. This may have affected the results; however, none of the con-
trols had chronic disease and their biopsy histology was normal. 
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Cow’s milk protein tolerance tests 
The children in Studies IV and V were considered to have delayed-type CMA on the basis of the 
open challenges.  A blinded challenge would have been scientifically valuable but was felt to be 
too laborious for clinical work.  On the other hand, a double-blind placebo-controlled setting was 
used in Study VI, and only one milk-hypersensitive subject was found among the young adults.  It 
is possible, either that an open challenge may overestimate the presence of CMA or that delayed 
CMA may be present in school-aged children but not in young adults. 
 None of the children of Studies IV and V had the obvious and immediate symptoms often seen 
in infants and young children with IgE-mediated CMA. Earlier studies with school-aged patients 
have included comprehensive measurements with the skin prick test, an atopic patch test, milk-
specific IgE and atopic changes in histology (eosinophilia), and in almost all cases the results have 
been negative and have not correlated with the results of the cow’s milk challenge (Kokkonen et 
al. 1999, Kokkonen et al. 2001c, Kokkonen et al. 2001b). For this reason, in this study series total 
and milk-specific IgE has not been routinely measured in patients who have delayed reactions. 
 
Lactose maldigestion tests 
Digestion of lactose was measured by several methods. The symptomatic response to the ingestion 
of lactose was carefully monitored by means of written symptom records, and subjects with hypo-
lactasia were diagnosed as being lactose intolerant according to their symptomatic response (I, II, 
VI). In Study I, the digestion of lactose was measured by a hydrogen breath test, which is reliable 
and non-invasive because no blood samples are required (Peuhkuri et al. 1998). However, the mi-
crobiota of some subjects may produce methane from hydrogen and so, in order to exclude errone-
ous negative results, in Study II the methane breath test was combined with the hydrogen breath 
test. The hydrogen breath test was considered too time-consuming for Study VI, which had a large 
study population, and therefore the alcohol-galactose test was used (Isokoski et al. 1972). Because 
of the young age of the subjects, as low an alcohol intake as possible was chosen, and the subjects 
ingested 150 mg of alcohol per body kg, the amount considered optimal by Pelto et al. (2000). 
Seven subjects, whose religious beliefs forbade the consumption of alcohol, took part in a conven-
tional lactose tolerance test with serum glucose measurements. Because of the relatively low alco-
hol intake and the two different lactose challenge methods used, in Study VI both the symptomatic 
subjects and the controls were genotyped for the C/C
-13910 variant of lactase persis-
tence/nonpersistence (adult-type hypolactasia) (Enattah et al. 2002, Kuokkanen et al. 2003, Rasin-
perä et al. 2004). The subjects of Studies IV and V were patients of Oulu University Hospital, and 
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when lactose intolerance was suspected, their lactose absorption was analysed by a routine lactose 
tolerance test with serial serum glucose measurements, as is customary in Finnish hospitals. 
 
Immunologic analysis 
The local cytokine environment of the intestine was investigated by rt-PCR analysis of biopsy 
specimens (V, VI), and ELISA and cytometric bead array analysis of incubated biopsy super-
natants (IV). Intestinal cytokines are usually studied by immunohistochemistry or in situ hybridi-
sation, which reveal the number of cytokine-specific cells in the tissue. Rt-PCR analysis of cyto-
kines in biopsy samples reflects the activation of cytokine-specific genes but the results do not 
always correlate with those from immunhistochemistry or in situ hybridisation. It is possible that 
the amount of cytokine-specific cells in tissue does not directly correlate with the amount of cyto-
kine secreted since the method does not reflect the activity of the cytokine-secreting cells. The 
amount of cytokine, or the balance between the cytokines in the tissue, is thus difficult to estimate 
with these methods. In Study IV, the release of cytokines from biopsy samples was measured in 
order to obtain a picture of the network of cytokines secreted in the intestinal environment. Since 
the biopsies were not stimulated with any mitogen or antigen during incubation, the result empha-
sises the biological significance of these intermediates.  
 
2  EFFECTS OF MILK HOMOGENISATION (I-III) 
 
No differences in the symptoms during the challenges with homogenised and unhomogenised 
milk, studied in three different settings (I, II), were discerned. Nor, in Study III, did antibody pro-
duction by milk-tolerant adults differ between the challenges with homogenised and unhomogen-
ised milk. Our findings accord with the data of previous double-blind placebo-controlled trials, in 
which no difference between homogenised and unhomogenised milk has been shown in the symp-
toms of cow’s milk allergic children (Hansen et al. 1987) or in the symptoms and complement-
receptor expression of milk hypersensitive, lactose-intolerant or control subjects (Pelto et al. 
2000). In animal studies, homogenised milk has been found to cause more intensive allergic reac-
tions than unhomogenised milk (Poulsen et al. 1987, Nielsen et al. 1989, Feng & Collins 1999), 
and our results do not exclude the possibility that homogenised and unhomogenised milk could 
induce different types of primary immunisation to cow’s milk antigens in immunologically intact 
infants. 
According to the interviews in Study II, in the milk interventions of Studies I and II the 2-5-
day milk challenges should have been long enough to produce symptoms, and the 5-10-day wash-
DISCUSSION 
  
 60 
out periods between the challenges, long enough to prevent any carry-over effect. However, in 
Study I, most of the subjects experienced more symptoms during the second challenge than during 
the first, regardless of which milk they were consuming. The carry-over effect did not cause this, 
because during the wash-out period between the challenges the subjects did not experience any 
more symptoms than during the run-in period. None of the subjects in Study I were lactose intoler-
ant, but they all experienced adverse gastrointestinal reactions during the milk challenges. It is 
possible, therefore, that some subjects who related their symptoms to milk homogenisation may 
have delayed-type cow’s milk-protein allergy reacting in a dose-response manner, and it can be 
hypothesised that the second milk challenge exceeded their tolerance limit. On the other hand, in 
Study II, the subjects experienced more symptoms during the first study milk period than during 
the second, irrespective of which milk they were ingesting. It has been suggested that lactose-
intolerant subjects become accustomed to small amounts of lactose in their diet (Pribila et al. 
2000), which could partially explain this finding. 
 
0
10
20
30
40
50
60
<10 y 10-20 y >20 y
Nu
m
be
r 
o
f s
u
bje
ct
s
Female
Male
 
Figure 17  Number of females and males subjectively reporting intolerance to homogenised milk (II). 
 
In the interviews in Study II, it was found that most subjects with subjective experience of a 
better tolerance of unprocessed than processed milk used small quantities of homogenised dairy 
products in their diet, either despite symptoms or even without symptoms. Most had found some 
dairy products they were able to consume without symptoms, and therefore immunological CMA 
cannot be the reason for their symptoms. This accords with a previous interview study, in which 
subjects with subjective intolerance to homogenised milk were able to consume some milk prod-
ucts without symptoms (Lagström et al. 2003). Interestingly, most of those children interviewed 
who were subjectively sensitive to processed milk were boys, whereas most of the adults inter-
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viewed were women (Fig. 17). The male sex is known to be immunologically weaker during child-
hood (Sears et al. 1993); on the other hand, functional gastrointestinal diseases seem to be more 
common among women than among men (Naliboff et al. 2003), which could partially explain our 
finding. 
In conclusion, these results do not show any significant difference in the tolerance of homoge-
nised or unhomogenised cow’s milk, either in subjects with self-reported symptoms suggestive of 
hypersensitivity to homogenised milk or in lactose-intolerant subjects, and no difference in cow’s 
milk protein-specific antibody responses to homogenised and unhomogenised milk in milk-
tolerant adults. The symptoms of the intolerant subjects were real but not affected by milk process-
ing. Therefore there is no physiological reason to recommend unhomogenised milk to lactose-
intolerant individuals, or to other symptomatic individuals. 
 
3 IMMUNOLOGICAL FINDINGS IN DELAYED-TYPE COW’S MILK ALLERGY (IV, 
V) 
 
Studies IV and V showed unique intestinal immune activation in delayed-type CMA, characterised 
by the up-regulation of both Th1- and Th2-type cytokines and a slight increase in the number of 
intraepithelial T cell populations.  
 
Cytokine network in delayed-type CMA 
The results of Studies IV and V concerning intestinal cytokine profiles in delayed CMA indicated 
that both Th1 and Th2 lymphocytes were locally activated in the intestine of these children, which 
suggests that delayed CMA is a separate entity and is different from atopic food allergy. This hy-
pothesis accords with a study by Hauer and co-authors (1997), in which patients with cow’s milk 
sensitive enteropathy (CMSE), a local delayed-type hypersensitivity, showed increased frequency 
of both IFN-γ- and IL-4-secreting lamina propria lymphocytes on duodenal mucosa compared to 
the controls, as detected by ELISPOT. In that study, both the children with CMSE and those with 
CMA showed increased IFN-γ, IL-4, IL-5 and IL-10 ELISPOTs in the blood compared to the con-
trols. However, IL-4 ELISPOTs were greater in the children with CMA compared to those with 
CMSE, which indicates differences in immediate and delayed reactions towards milk.  
Our finding of increased IFN- release in children with delayed CMA (IV) accords with a 
study by Veres et al. (2003), in which children with untreated delayed-type food allergy to cow’s 
milk and/or cereals had elevated densities of IFN- cells and high expression of IFN- mRNA in 
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the duodenum, detected by immunohistochemistry and in situ hybridisation methods. These find-
ings suggest that the activation of the Th1 immune response is associated with gastrointestinal 
hypersensitivity. However, in Study V, we could not demonstrate increased expression of IFN-γ 
mRNA in delayed CMA. It may be that the amount of cytokine-specific mRNA does not correlate 
with the actual production of the protein. This is supported by a study in which IFN-γ-secreting 
cells dominated in the Peyer’s patches and the ileal lamina propria in healthy children who had no 
signs of gastrointestinal disease, but the mRNA levels of IL-4 and IL-10 were either higher or 
equivalent to IFN-γ mRNA (Hauer et al. 1998). This suggests that, at least in healthy intestinal 
mucosa, the number of IFN-γ-secreting cells is higher than that of IL-4- or IL-10-secreting cells, 
the last two, however, being strongly activated and expressing abundant mRNA.  
The increased secretion of IL-4 in Study IV, and the increased expression of IL-6 and CCR-4 
mRNA in Study V supports the view that in delayed CMA the Th2 lymhocytes are activated, too. 
CCR-4 is a chemokine receptor expressed in Th2 lymphocytes and associated with hypersensitive 
states (Sallusto et al. 1998, Imai et al. 1999), and IL-6 supports the so-called Th2-type immune 
response, since it activates IL-4-secreting cells and contributes to mucosal IgA production (Bea-
gley et al. 1989, Rincon et al. 1997). Markers of Th2 lymphocyte activation suggest that these chil-
dren may still show some signs of local IgE-mediated reactions, since many of them had an IgE-
mediated allergy in infancy. Indeed, Lin et al. (2002) found reduced numbers of IFN-+ cells and 
increased numbers of IL-4+ cells, detected by immunostaining, in duodenal biopsies of sympto-
matic food-allergic adults with negative serum IgE, suggesting a localised IgE-mediated response 
in the gastrointestinal tract during the symptomatic period of these patients. 
The activation of Th2 lymphocytes indicates a failure to suppress the immune responses 
against luminal cow’s milk antigens to tolerance. However, in Study V, the mRNA expression of 
regulatory cytokine TGF-β showed no difference, either in delayed CMA or in celiac disease, 
compared to the controls. On the other hand, when the children in Study IV who had delayed 
CMA were divided into different diet groups, those who avoided cow’s milk showed up-regulation 
of TGF-. The decreased release of TGF- among those who were exposed to dietary cow’s milk 
supports earlier findings of the down-regulation of TGF- in young children with food allergies 
(Pérez-Machado et al. 2003). TGF-, produced by regulatory T cells, is an inhibitory cytokine rec-
ognised as a key regulator of immunological homeostasis and inflammatory responses, and is as-
sociated with the development of oral tolerance (Yazdanbakhsh et al. 2002, Umetsu et al. 2003). 
Interestingly, an increase of IL-10 was also seen in those children with delayed CMA who con-
sumed milk (IV). IL-10 is a cytokine with a dual function: it may have anti-inflammatory activity 
and inhibit Th1 and Th2 responses, and it is also a mediator of T regulatory cell activities. The 
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anti-inflammatory role of IL-10 in the intestine has recently been questioned, and the protective 
effect of IL-10 may merely be an indirect consequence of its effect on TGF-β secretion (Fuss et al. 
2002). In Study IV, the release of IL-10 correlated with the levels of IFN- in all the study groups, 
which suggests that IL-10 reflects inflammation in the human mucosa, as earlier reported in stud-
ies on rheumatoid arthritis and spondyloarthropathy (Van Damme et al. 2001, Nissinen et al. 
2004). Thus, our finding of up-regulated IFN- and IL-10 may indicate intestinal inflammation and 
disorder in the permeability of the mucosa in children with delayed CMA. 
 
Endoscopic findings and intraepithelial T cells in delayed CMA 
The endoscopic, histological and imunohistochemical findings of Studies IV and V confirm previ-
ous findings concerning the mucosal state in the duodenum and ileum of patients with delayed 
CMA (Kokkonen et al. 2000, Kokkonen et al. 2001b). Lymphonodular hyperplasia of the intestine 
has been reported in children with gastrointestinal symptoms (Kokkonen & Karttunen 2002, 
Kokkonen et al. 2002), and this was also a typical finding in the children of our Studies IV and V. 
This seems not to be the case among young adults, as none of the symptomatic young adults of 
Study VI had LNH of the duodenal bulb or the terminal ileum. 
A massive increment of intraepithelial CD3+, αβ+ and γδ+ T cells is a typical characteristic of 
celiac disease (Kontakou et al. 1995, Westerholm-Ormio et al. 2002, Veres et al. 2003), as was 
seen in the children with celiac disease in Studies IV and V, and was also reported to a lesser ex-
tent in food-induced gastrointestinal hypersensitivity (Spencer et al. 1991, Savilahti 2000, 
Kokkonen et al. 2001b). In Study IV, the densities of the intraepithelial T cells were significantly 
elevated in those children with delayed CMA who were exposed to cow’s milk but not in those 
who avoided it, which reflects the down-regulation of intestinal immune activation in the treated 
disease. In Study V, we found mild elevation in the densities of intraepithelial γδ+ T cells in the 
duodenum, and highly elevated densities of + T cells and the +/CD3+ ratio in the ileum of de-
layed CMA patients. In Study V, the up-regulation of cytokine expression was also most pro-
nounced in the samples from the terminal ileum, where the signs of intestinal hypersensitivity (i.e. 
prominent LNH and an increase in γδ+ T cells) were most prominent in the children with delayed 
CMA. In delayed CMA, no increase of mononuclear cell infiltration in the lamina propria, no vil-
lous atrophy and no accumulation of immune cells outside the germinal centres was observed ei-
ther in duodenal or in ileal biopsy samples (IV, V). 
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4  FINDINGS IN IMMUNE-LIKE GASTROINTESTINAL SYNDROME (VI) 
 
The main aim of Study VI was to evaluate the occurrence of hypersensitivity to cow’s milk protein 
in young adults with gastrointestinal complaints similar to those described in younger children in 
Studies IV and V. However, we were not able to find even one case with lymphonodular hyperpla-
sia. In a blinded challenge, cow’s milk yielded the same amount of symptoms as the placebo soy 
drink.  
Almost half the subjects reported having suffered some abdominal complaints during the pre-
vious year, but in most cases the symptoms appeared infrequently and did not disturb their normal 
life. In Study VI, in agreement with earlier studies on children (Kokkonen et al. 2001b, Kokkonen 
et al. 2004), 10% of the young adults reported intensive and major gastrointestinal complaints. The 
frequency of gastrointestinal symptoms subjectively related to consumption of cow’s milk was 
surprisingly high, a quarter of all the subjects. Lactose intolerance was present in 13% of the study 
subjects, and 3% claimed to have milk allergy, both the intolerance and the allergy being, in most 
cases, self-diagnosed. Pelto et al. (1999) calculated that the frequency of cow’s milk protein hyper-
sensitivity is 3-6% among young adults in Finland, while the prevalence of lactose intolerance was 
estimated to be about 6%. Our negative results from the blinded milk-protein challenge and the 
hypolactasia gene test do not support these estimates. In the placebo-controlled low-lactose milk 
challenge, milk protein was found to cause pronounced symptoms in only two (one of whom was 
lactose intolerant) of the 23 subjects who completed the challenge, and four subjects out of the 47 
symptomatic subjects had the C/C
-13910 genotype associated with low lactase activity (Enattah et al. 
2002, Kuokkanen et al. 2003, Rasinperä et al. 2004). According to these observations there seems 
to be a very marked discrepancy between self-observed food-related reactions and definitely diag-
nosed hypersensitivity or intolerance states as demonstrated by many earlier investigators (Suarez 
et al. 1995, Vesa et al. 1998, Vernia et al. 2004). The problem is that the avoidance of milk and 
dairy products by symptomatic subjects, also seen as decreased levels of cow’s milk specific anti-
bodies, often leads to impaired nutrient intake (Weinberg et al. 2004). 
Although cow’s milk did not trigger gastrointestinal symptoms, our results suggest that in-
flammatory mechanisms are involved in food-related gastrointestinal complaints, because, com-
pared to the controls, the symptomatic cases as a group showed higher concentrations of circulat-
ing sICAM-1 and a tendency towards the up-regulation of TGF- and IL-12p35 mRNA expression 
in the mucosal biopsies. IL-12 is a monocyte-derived cytokine which enhances IFN-γ up-
regulation. Soluble ICAM-1, induced by IFN-γ, is important for eosinophil and neutrophil adhe-
sion, and a high concentration of sICAM-1 in the plasma has been observed as a marker of persis-
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tent airway inflammation in asthmatic patients (Kokuludag et al. 2002). Exposure to cow’s milk 
during infancy also induces circulating sICAM-1, reflecting an inflammatory response to orally-
ingested foreign proteins (Paronen et al. 1996). To conclude, the subjects with food-related gastro-
intestinal symptoms had increased activation of the immune system and markers of inflammation 
of the intestinal mucosa. Supporting this, the symptomatic patients tended to have higher counts of 
intraepithelial CD3+ T cells in the duodenal mucosa compared to the controls.  
In conclusion, 10% of the young Finnish adults reported major gastrointestinal complaints, 
24% reported cow’s milk-induced gastrointestinal symptoms, and 13% did not drink milk at all in 
its primary, liquid form. However, in a blind challenge, cow’s milk protein-induced symptoms 
were rare and similar to those of a placebo soy drink. Yet markers were found of skewed immune 
response on the gastrointestinal mucosa in the symptomatic subjects. The food-related gastrointes-
tinal symptoms of young adults seem to be caused by the unspecific and unknown traits of an al-
tered mucosal immune response rather than being triggered by cow’s milk, as is often suspected by 
the patient. This new entity of intestinal immune-mediated disorder may be a self-perpetuating 
disease showing fluctuations of symptoms. An autoimmune nature of the state, at least in a sub-
group of the affected subjects, cannot be ruled out, and this hypothesis is supported by the obser-
vation that the HLA DQ*02 allele predisposing to autoimmunity was almost twice as common 
among the symptomatic individuals as among the rest. 
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CONCLUSIONS 
 
In the present study, the effects of cow’s milk and its processing on gastrointestinal symptoms and 
delayed-type, (i.e. non-IgE-mediated), immune responses were studied. Based on the results pre-
sented in this thesis, the main conclusions are as follows: 
 
1. Homogenised and unhomogenised cow’s milk was tolerated equally by subjects with self-
reported symptoms suggestive of hypersensitivity to homogenised milk, and by lactose-
intolerant subjects. Nor was any difference in the production of cow’s milk protein-specific 
antibodies discerned in milk-tolerant adults during the challenges with homogenised and 
unhomogenised cow’s milk. The hypersensitivity reactions of the intolerant subjects were 
real but the processing of milk did not affect the symptoms. The possibility cannot be ig-
nored that some individuals may benefit from unprocessed milk, but there is no evidence-
based physiological reason to recommend unhomogenised milk to lactose-intolerant sub-
jects in general, or to other symptomatic individuals. 
 
2. Children with non-IgE-mediated, delayed-type CMA showed characteristic local cytokine 
activation in the intestine, consisting of the high release of IFN- and the up-regulated ex-
pression of IL-6 and CCR-4 mRNA combined with some evidence of a reduced IL-2 
mRNA expression. These results suggest that delayed-type CMA is a local intestinal im-
mune-activation state showing activation of both Th1 and Th2 lymphocytes. 
 
3. No evidence of an occurrence of similar hypersensitivity to cow’s milk protein as described 
in younger children was found in young adults with gastrointestinal complaints. In a blind 
challenge, cow’s milk protein-induced symptoms were rare and similar to those of a pla-
cebo soy drink. However, markers of skewed immune response on the gastrointestinal mu-
cosa in the symptomatic subjects were found. The food-related gastrointestinal symptoms 
of the young adults seemed to be caused by the unspecific and unknown traits of an altered 
mucosal immune response rather than being triggered by cow’s milk, the latter being often 
suspected by the patient. This new entity of intestinal immune-mediated disorder may be a 
self-perpetuating disease showing fluctuation of symptoms. An autoimmune nature of the 
state, at least in a subgroup of the subjects affected, cannot be ruled out, and this hypothesis 
is supported by the observation that the HLA DQ*02 allele predisposing to autoimmunity 
was almost twice as common among the symptomatic individuals as among the rest. 
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4. In a questionnaire, 10% of the young Finnish adults reported major gastrointestinal com-
plaints, 24% reported cow’s milk-induced gastrointestinal symptoms and 13% did not 
drink any milk as such. However, in a blind challenge only one young adult was found to 
be hypersensitive to cow’s milk. According to these observations there seems to be a very 
marked discrepancy between self-observed food-related reactions and definitely-diagnosed 
hypersensitivity or intolerance states. 
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